Your SlideShare is downloading. ×
0
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Catalogue eng Tecnoss Osteobiol 2012   partea a II-a
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Catalogue eng Tecnoss Osteobiol 2012 partea a II-a

2,548

Published on

Published in: Business, Technology
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
2,548
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
66
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. PRODUCTS BONE SUBSTITUTES MEMBRANES AND BARRIERS SPECIFIC PRODUCTS Source: Courtesy of Dr Ulf Nannmark, Göteborg University, Sweden 57
  • 2. Bone substitutes Maxillary sinus lift grafted with OsteoBiol® mp3: simultaneous implant placement and simultaneous horizontal augmentation Source: Courtesy of Dr Rosario Sentineri, Genova, Italy
  • 3. OsteoBiol® bone substitutes PRODUCTS BONE SUBSTITUTES HETEROLOGOUS BONE Inorganic Organic component component (mineral) (collagen) CORTICAL BONE CANCELLOUS BONE Collagenated mix Collagen gel TO TO TO DY DY DY USE USE USE REA REA REA Gen-Os mp3 Putty Gel 40 Gel 0100% collagenated 90% bone mix 80% bone mix 60% bone mix 100% bone mix 10% Gel 0 20% Gel 0 40% Gel 0 collagen gel Heterologous Heterologous Heterologous Heterologous cortico-cancellous cortico-cancellous cortico-cancellous cortico-cancellous collagenated bone mix collagenated collagenated collagenated pre-hydrated bone mix pre-hydrated bone paste pre-hydrated bone gelSource: Tecnoss s.r.l. 59
  • 4. Gen-Os Heterologous cortico-cancellous collagenated bone mix Detail of an OsteoBiol® Gen-Os granule: vascular canal entrance with evident centralised osteonic structure Source: Courtesy of Dr Ulf Nannmark, University of Göteborg, Sweden
  • 5. Characteristics | Gen-Os PRODUCTS BONE SUBSTITUTESCHARACTERISTICS HANDLINGA natural replicate of autologous bone, Gen-Os must always be hydrated andGen-Os conserves the same intimate thoroughly mixed with a few drops ofstructures(1) (matrix and porous form) and sterile physiological solution to activate itspresents a high osteoconductive activity(2). collagen matrix and to enhance itsIt is biocompatible and bioavailable, as adhesivity; it can also be mixed either withrecognized by tests made according to the OsteoBiol® Gel 0 or with patients blood. IfISO 10993 method conducted at the necessary it can as well be mixed with theUniversità degli Studi di Torino. drug selected for surgery.Gen-Os is gradually resorbable and ADVANTAGESprovides support in bone neoformation Gen-Os expands up to 50% in volumehelping to preserve the original graft after hydration with sterile saline: hydrated Tissue of originshape and volume (osteoconductive collagen contained in each granule also Cortico-cancellous heterologous bone mixproperty). increases sensibly biomaterial adhesivity. Tissue collagenMoreover, thanks to its collagen content, Preserved 150%the product facilitates blood clotting and Physical form 100% Slightly radiopaque granulesthe subsequent invasion of repairing andregenerative cells, favouring restitutio ad 50% Compositionintegrum of missing bone. Dried Hydrated 100% granulated mix 0%Because of its marked “hydrophilia”, it can Volume Granulometry 250-1000 µmfunction as a carrier for selected OsteoBiol® Gen-Os SEM image of OsteoBiol® Gen-Os granules. Magnif. x50medications and drugs. Source: Tecnoss s.r.l. Source: Courtesy of Dr Ulf Nannmark, Göteborg University, Sweden Re-entry time 4/5 months, depending on grafting site characteristics Packaging Vial: 0.25 g, 0.5 g, 1.0 g, 2.0 g Product codes M1052FS | 1 Vial | 0.25 g | Porcine M1052FE | 1 Vial | 0.25 g | Equine M1005FS | 1 Vial | 0.5 g | Porcine M1005FE | 1 Vial | 0.5 g | Equine M1010FS | 1 Vial | 1.0 g | Porcine M1010FE | 1 Vial | 1.0 g | Equine M1020FS | 1 Vial | 2.0 g | Porcine M1020FE | 1 Vial | 2.0 g | EquineSEM image of an OsteoBiol® Gen-Os granule highlighting the porosity of the OsteoBiol® bone matrixSource: Courtesy of Dr Ulf Nannmark, Göteborg University, Sweden 61
  • 6. Gen-Os Clinical indications MAXILLARY PERI-IMPLANT SCIENTIFIC PUBLICATIONS ON OSTEOBIOL® GEN-OS SINUS FLOOR LESIONS BARONE A, CRESPI R, ALDINI NN, FINI M, GIARDINO R,COVANI U AUGMENTATION MAXILLARY SINUS AUGMENTATION: HISTOLOGIC AND HISTOMORPHOMETRIC ANALYSIS INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL IMPLANTS, 2005 JUL-AUG;20(4):519-25 BARONE A, SANTINI S, SBORDONE L, CRESPI R, COVANI U A CLINICAL STUDY OF THE OUTCOMES AND COMPLICATIONS ASSOCIATED WITH MAXILLARY SINUS AUGMENTATION INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL IMPLANTS, 2006 JAN-FEB;21(1):81-5 COVANI U, BARONE A, CORNELINI R, CRESPI R CLINICAL OUTCOME OF IMPLANTS PLACED IMMEDIATELY For more information on For more information on AFTER IMPLANT REMOVAL JOURNAL OF PERIODONTOLOGY, 2006 APR;77(4):722-7 LATERAL ACCESS SINUS LIFT DEHISCENCES AND FENESTRATIONS please see page 36 please see page 24 CARDAROPOLI D, CARDAROPOLI G PRESERVATION OF THE POSTEXTRACTION ALVEOLAR RIDGE: A CLINICAL AND HISTOLOGIC STUDY INTERNATIONAL JOURNAL OF PERIODONTICS AND RESTORATIVE INTRABONY OSTEOTOME DENTISTRY, 2008 OCT;28(5):469-77 DEFECTS SINUS FLOOR NANNMARK U, SENNERBY L THE BONE TISSUE RESPONSES TO PREHYDRATED AND AUGMENTATION COLLAGENATED CORTICO-CANCELLOUS PORCINE BONE GRAFTS: A STUDY IN RABBIT MAXILLARY DEFECTS CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2008 DEC;10(4):264-70. EPUB 2008 JAN 30 FIGUEIREDO M, HENRIQUES J, MARTINS G, GUERRA F, JUDAS F, FIGUEIREDO H PHYSICOCHEMICAL CHARACTERIZATION OF BIOMATERIALS COMMONLY USED IN DENTISTRY AS BONE SUBSTITUTES – COMPARISON WITH HUMAN BONE JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B: APPLIED BIOMATERIALS, EPUB 10 NOVEMBER 2009 IN WILEY INTERSCIENCE For more information on For more information on CRESPI R, CAPPARÈ P GHERLONE E , DENTAL IMPLANTS PLACED IN EXTRACTION SITES GRAFTED PERIODONTAL REGENERATION CRESTAL ACCESS SINUS LIFT WITH DIFFERENT BONE SUBSTITUTES: RADIOGRAPHIC please see page 50 please see page 30 EVALUATION AT 24 MONTHS JOURNAL OF PERIODONTOLOGY, 2009 OCT; 80(10):1616-1621 SCARANO A, CARINCI F, ASSENZA B, PIATTELLI M, MURMURA G, TWO-WALL SOCKETS PIATTELLI A DEFECTS PRESERVATION VERTICAL RIDGE AUGMENTATION OF ATROPHIC POSTERIOR MANDIBLE USING AN INLAY TECHNIQUE WITH A XENOGRAFT WITHOUT MINISCREWS AND MINIPLATES: CASE SERIES CLINICAL ORAL IMPLANTS RESEARCH, 2011 OCT;22(10):1125-30 PAGLIANI L, ANDERSSON P LANZA M, NAPPO A, VERROCCHI D, , VOLPE S, SENNERBY L A COLLAGENATED PORCINE BONE SUBSTITUTE FOR AUGMENTATION AT NEOSS IMPLANT SITES: A PROSPECTIVE 1-YEAR MULTICENTER CASE SERIES STUDY WITH HISTOLOGY CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2010 OCT 26 EPUB CRESPI R, CAPPARÉ P ROMANOS GE, MARIANI E, BENASCIUTTI E, , GHERLONE E CORTICOCANCELLOUS PORCINE BONE IN THE HEALING OF HUMAN For more information on For more information on EXTRACTION SOCKETS: COMBINING HISTOMORPHOMETRY HORIZONTAL AUGMENTATION ALVEOLAR REGENERATION WITH OSTEOBLAST GENE EXPRESSION PROFILES IN VIVO please see page 42 please see page 18 INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL IMPLANTS 2011 JUL - AUG; 26(4):866-72 Source: Tecnoss® Dental Media Library 62
  • 7. The advantages of dual-phase biomaterials | Gen-Os PRODUCTS BONE SUBSTITUTESCLINICAL INDICATIONS SUMMARY CLINICAL INDICATIONS OVERVIEW a unique biomaterial, consisting of mineral BIBLIOGRAPHYOral surgery: granulomas, dentigenous A bone graft is a material used to repair a component and organic matrix, with a (1) FIGUEIREDO M, HENRIQUES J, MARTINS G, GUERRA F, JUDAScysts and ridge split. bone defect or deficiency contour and/or porous surface extremely similar to F, FIGUEIREDO H volume. The use of these materials in autogenous bone and able to resorb PHYSICOCHEMICAL CHARACTERIZATION OF BIOMATERIALS COMMONLY USED IN DENTISTRY AS BONEPeriodontology: filler of deep intrabony progressively while new bone formation regenerative procedures is based on the SUBSTITUTES - COMPARISON WITH HUMAN BONEdefects and furcations. takes place(2). JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B: assumption that they are osteoconductive APPLIED BIOMATERIALS, 2010FEB; 92(2):409-19Implantology: universal filler used in i.e. serve as scaffold for new bone Gen-Os, a cortico-cancellous bone mix, (2) NANNMARK U, SENNERBY L THE BONE TISSUE RESPONSES TO PREHYDRATED ANDtreatment of dehiscences and formation. The entire OsteoBiol® line has been the first product developed with COLLAGENATED CORTICO-CANCELLOUS PORCINE BONEperiimplantitis, two wall defects, lateral consists of xenografts, i.e. biomaterials this innovative biotechnology and, due to GRAFTS: A STUDY IN RABBIT MAXILLARY DEFECTS CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2008and crestal access sinus lift. When needed deriving from heterologous bone and soft its universal use, still is today the most DEC;10(4):264-70. EPUB 2008 JAN 30Gen-Os graft and protected with tissues. demanded from the market. (3) CARDAROPOLI D, CARDAROPOLI GOsteoBiol® membranes or OsteoBiol® PRESERVATION OF THE POSTEXTRACTION ALVEOLAR The Tecnoss® patented manufacturing Gen-Os has been successfully used and RIDGE: A CLINICAL AND HISTOLOGIC STUDYcortical laminae. THE INTERNATIONAL JOURNAL OF PERIODONTICS AND process used to obtain these materials is documented for alveolar ridge RESTORATIVE DENTISTRY, 2008, 28: 469-477 able to achieve biocompatibility preserving preservation(3) in combination with (4) BARONE A, CRESPI R, NICOLI ALDINI N, FINI M, GIARDINO R, part of the collagen matrix of the animal Evolution membranes: the application of COVANI U MAXILLARY SINUS AUGMENTATION: HISTOLOGIC AND bone and avoiding at the same time high this biomaterial limits significantly the HISTOMORPHOMETRIC ANALYSIS THE INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL temperatures that would cause alveolar ridge width reduction that would IMPLANTS, 2005, 20: 519-525 ceramization of the granules: the result is naturally occur with spontaneous healing, (5) BARONE A, SANTINI S, SBORDONE L, CRESPI R, COVANI U A CLINICAL STUDY OF THE OUTCOMES AND preserving thus the alveolar ridge volume COMPLICATIONS ASSOCIATED WITH MAXILLARY SINUS and allowing a correct second stage AUGMENTATION THE INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL implant placement. Gen-Os is also IMPLANTS, 2006, 26: 81-85 indicated for lateral access maxillary sinus (6) VOZZA I, SCARANO A, QUARANTA M CLINICAL AND HISTOLOGICAL STUDY ON MAXILLARY lift(4,5,6) and dehiscence regeneration(7), SINUS LIFT AND FILLING WITH COLLAGENIZED PIG BONE always in association with Evolution ITALIAN JOURNAL OF OSTEOINTEGRATION, 2004, 4: 19-23 membranes. (7) COVANI U, BARONE A, CORNELINI R, CRESPI R CLINICAL OUTCOME OF IMPLANTS PLACED IMMEDIATELY AFTER IMPLANT REMOVAL Ongoing studies are also proving its JOURNAL OF PERIODONTOLOGY, 2006, 77: 722-727 effectiveness in periodontal regeneration of deep intrabony defects. Due to its collagen content, once hydrated Gen-Os becomes very sticky and hydrophylic: it combines therefore extremely well with blood and is very stable once applied into the grafting site. Its cortico-cancellous composition allows a progressive resorption of osteoclastic type, with in parallel a similar rate of new bone formation(2): these unique properties allow a very good graft volume preservation, a healthy new bony tissue and ultimately, aIntrabony defect grafted with OsteoBiol® Gen-OsSource: Courtesy of Dr Roberto Rossi, Genova, Italy successful implant rehabilitation. 63
  • 8. mp3 Heterologous cortico-cancellous collagenated pre-hydrated bone mix Histology on maxillary sinus biopsy taken at 24 months. 48% new bone formation, 13% residual granules Source: Biopsy by Dr Roberto Rossi, Genova, Italy. Histology by Dr Ulf Nannmark, University of Göteborg, Sweden
  • 9. Characteristics | mp3 PRODUCTS BONE SUBSTITUTESCHARACTERISTICS HANDLINGHeterologous origin biomaterial made of mp3 is available in ready-to-use syringes and can be easily grafted avoiding the600-1000 µm pre-hydrated collagenated hydration and manipulation phases.cortico-cancellous granules, properly After adapting the material to the defect shape, it is necessary to remove non stablemixed with OsteoBiol® Gel 0. Thus, it is residues before proceeding to soft tissue suture.possible both skipping the hydration phaseand decreasing the risk of accidentalexposure of material to pathogens duringmanipulation and grafting phases;furthermore the syringe is flexible andideal to simplify grafting in the receivingsite. Tissue of originThe granules are endowed with Cortico-cancellous heterologous bone mixcharacteristics very similar to human Tissue collagenmineral bone(1), and can be used as an Preserved plus an additional 10% OsteoBiol®alternative to autologous bone. Gel 0 (collagen gel)Their natural micro-porous consistency Physical form Pre-hydrated granules and collagen gelfacilitates new bone tissue formation indefect sites and accelerates the Compositionregeneration process. 90% granulated mix, 10% collagen gel GranulometryGradually resorbable(2), it preserves the 600-1000 µmoriginal graft shape and volume Re-entry time(osteoconductive property). Moreover, About 5 monthsthanks to its collagen content, the productfacilitates blood clotting and the Packaging Syringe: 1.0 cc, 3 x 0.5 cc, 3 x 1.0 ccsubsequent invasion of repairing and Maxillary sinus grafted with OsteoBiol® mp3regenerative cells. Source: Courtesy of Dr Gianluca Reato, Mestre, Italy Product codes A3005FS | 1 Syringe | 1.0 cc | Porcine A3005FE | 1 Syringe | 1.0 cc | Equine A3015FS | 3 Syringe | 3x0.5 cc | Porcine A3015FE | 3 Syringe | 3x0.5 cc | Equine A3030FS | 3 Syringe | 3x1.0 cc | Porcine A3030FE | 3 Syringe | 3x1.0 cc | EquinePost-extractive alveolous grafted with OsteoBiol® mp3 Horizontal augmentation performed with OsteoBiol® mp3 Maxillary sinus grafted with OsteoBiol® mp3Source: Courtesy of Dr Roberto Rossi, Genova, Italy Source: Courtesy of Prof Dr Jose Luis Calvo Guirado, Murcia, Spain Source: Courtesy of Dr Antonio Barone and Prof Ugo Covani, Lido di Camaiore, Italy 65
  • 10. mp3 Clinical indications MAXILLARY SCIENTIFIC PUBLICATIONS ON OSTEOBIOL® MP3 SINUS FLOOR BARONE A, SANTINI S, MARCONCINI S, GIACOMELLI L, GHERLONE E, AUGMENTATION COVANI U OSTEOTOMY AND MEMBRANE ELEVATION DURING THE MAXILLARY SINUS AUGMENTATION PROCEDURE. A COMPARATIVE STUDY: PIEZOELECTRIC DEVICE VS. CONVENTIONAL ROTATIVE INSTRUMENTS CLINICAL ORAL IMPLANTS RESEARCH, 2008 MAY;19(5):511-5. EPUB 2008 MAR 26 BARONE A, ALDINI NN, FINI M, GIARDINO R, CALVO GUIRADO JL, COVANI U XENOGRAFT VERSUS EXTRACTION ALONE FOR RIDGE PRESERVATION AFTER TOOTH REMOVAL: A CLINICAL AND HISTOMORPHOMETRIC STUDY For more information on JOURNAL OF PERIODONTOLOGY, 2008 AUG;79(8):1370-7 LATERAL ACCESS SINUS LIFT NANNMARK U, SENNERBY L see page 36 THE BONE TISSUE RESPONSES TO PREHYDRATED AND COLLAGENATED CORTICO-CANCELLOUS PORCINE BONE GRAFTS: A STUDY IN RABBIT MAXILLARY DEFECTS CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2008 POST-EXTRACTIVE DEC;10(4):264-70. EPUB 2008 JAN 30 SOCKETS CALVO GUIRADO JL, GOMEZ MORENO G, LOPEZ MARI L, ORTIZ RUIZ AJ, GUARDIA J ATRAUMATIC MAXILLARY SINUS ELEVATION USING THREADED BONE DILATORS FOR IMMEDIATE IMPLANTS. A THREE-YEAR CLINICAL STUDY MEDICINA ORAL, PATOLOGIA ORAL Y CIRUGIA BUCAL, 2010 MAR 1; 15(2):E366-70 BARONE A, RICCI M, COVANI U, NANNMARK U, AZARMEHR I, CALVO-GUIRADO JL MAXILLARY SINUS AUGMENTATION USING PREHYDRATED CORTICOCANCELLOUS PORCINE BONE: HYSTOMORPHOMETRIC EVALUATION AFTER 6 MONTHS CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2010 MAY 11 EPUB For more information on PAGLIANI L, ANDERSSON P LANZA M, NAPPO A, VERROCCHI D, , ALVEOLAR REGENERATION VOLPE S, SENNERBY L see page 18 A COLLAGENATED PORCINE BONE SUBSTITUTE FOR AUGMENTATION AT NEOSS IMPLANT SITES: A PROSPECTIVE 1-YEAR MULTICENTER CASE SERIES STUDY WITH HISTOLOGY CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2010 OCT TWO-WALL “For many years Doctors enjoyed the superb 26 EPUB DEFECTS clinical performances offered by the universal BARONE A, RICCI M, CALVO GUIRADO JL, COVANI U granulated product OsteoBiol® Gen-Os and a BONE REMODELLING AFTER REGENERATIVE PROCEDURES AROUND IMPLANTS PLACED IN FRESH EXTRACTION SOCKETS: common technique was to mix Gen-Os with AN EXPERIMENTAL STUDY IN BEAGLE DOGS additional collagen gel (OsteoBiol® Gel 0). CLINICAL ORAL IMPLANTS RESEARCH, 2010 CALVO GUIRADO JL, RAMIREZ FERNANDEZ MP NEGRI B, DELGADO , After many years of research Tecnoss® was RUIZ RA, MATÉ SANCHEZ DE VAL JE, GOMEZ MORENO G EXPERIMENTAL MODEL OF BONE RESPONSE TO able to introduce a revolutionary product, COLLAGENIZED XENOGRAFTS OF PORCINE ORIGIN collagenated, pre-hydrated and ready-to-use, (OSTEOBIOL® MP3): A RADIOLOGICAL AND HISTOMORPHOMETRIC STUDY offering unprecedented clinical performances CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2011 MAR and unique handling properties” 31, EPUB AHEAD OF PRINT For more information on HINZE M, VRIELINCK L, THALMAIR T, WACHTEL H, BOLZ W HORIZONTAL AUGMENTATION Giuseppe Oliva MD ZYGOMATIC IMPLANT PLACEMENT IN CONJUCTION WITH see page 42 R&D Director SINUS BONE GRAFTING: THE "EXTENDED SINUS ELEVATION Tecnoss S.r.l. TECHNIQUE". A CASE-COHORT STUDY Source: Tecnoss® Dental Media Library 2011; 1:188-197 66
  • 11. Ultimate performance and handling PRODUCTS BONE SUBSTITUTESCLINICAL INDICATIONS SUMMARY BIBLIOGRAPHYOral surgery and implantology: thanks to (1) FIGUEIREDO M, HENRIQUES J, MARTINS G, GUERRA F,its particular formulation and JUDAS F, FIGUEIREDO H PHYSICOCHEMICAL CHARACTERIZATION OFgranulometry, mp3 is ideal for grafting in BIOMATERIALS COMMONLY USED IN DENTISTRY AS BONEsurgical procedures of maxillary sinus lift SUBSTITUTES - COMPARISON WITH HUMAN BONE JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B:with lateral access(1,2). APPLIED BIOMATERIALS, 2010FEB; 92(2):409-19 (2) NANNMARK U, SENNERBY LA membrane OsteoBiol® Evolution or THE BONE TISSUE RESPONSES TO PREHYDRATED ANDOsteoBiol® Special is recommended to COLLAGENATED CORTICO-CANCELLOUS PORCINE BONE GRAFTS. A STUDY IN RABBIT MAXILLARY DEFECTScover the antrostomy. CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2008, 10: 264-270CLINICAL INDICATIONS OVERVIEW Maxillary sinus grafted with OsteoBiol® mp3 Antrostomy covered with OsteoBiol® Special (3) BARONE A, SANTINI S, MARCONCINI S, GIACOMELLI L, Source: Courtesy of Dr Roberto Rossi, Genova, Italy Source: Courtesy of Dr Antonio Barone and Prof Ugo Covani, Lido diA bone graft is a material used to repair a Camaiore, Italy GHERLONE E, COVANI U OSTEOTOMY AND MEMBRANE ELEVATION DURING THEbone defect or deficiency contour and/or MAXILLARY SINUS AUGMENTATION PROCEDURE. Avolume. COMPARATIVE STUDY: PIEZOELECTRIC DEVICE VS. CONVENTIONAL ROTATIVE INSTRUMENTS CLINICAL ORAL IMPLANTS RESEARCH, 2008 MAY;19(5):511-5.The use of these materials in regenerative EPUB 2008 MAR 26procedures is based on the assumption (4) BARONE A, RICCI M, COVANI U, NANNMARK U,that they are osteoconductive i.e. serve as AZARMEHR I, CALVO GUIRADO JL MAXILLARY SINUS AUGMENTATION USING PREHYDRATEDscaffold for new bone formation. CORTICOCANCELLOUS PORCINE BONE: HYSTOMORPHOMETRIC EVALUATION AFTER 6 MONTHSThe entire OsteoBiol® line consists of CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2010 MAY 11 EPUBxenografts, i.e. biomaterials deriving fromheterologous bone and soft tissues. Horizontal augmentaton performed with OsteoBiol® mp3 Antrostomy covered with OsteoBiol® EvolutionThe Tecnoss® patented manufacturing Source: Courtesy of Dr Rosario Sentineri, Genova, Italy Source: Courtesy of Dr Roberto Rossi, Genova, Italyprocess used to obtain these materials isable to achieve biocompatibility preserving mp3 main indication is lateral access maxillary sinus lift(2), always in association withpart of the collagen matrix of the animal Evolution membranes: the mp3 syringe can be directly applied into the bony windowbone and avoiding at the same time high without having to mix the mp3 granules with saline. Due to its collagen gel content, mp3temperatures that would cause allows an excellent graft stability while its hydrophilia guarantees quick blood absorptionceramization of the granules: the result is a and therefore the necessary graft vascularization.unique biomaterial, consisting of mineral mp3 has also been successfully used in combination with Evolution membranes forcomponent and organic matrix, with a alveolar ridge preservation(3): the application of this biomaterial limits significantly theporous surface extremely similar to alveolar ridge width and height reduction that would naturally occur with spontaneousautogenous bone and able to resorb healing, preserving thus the alveolar ridge volume and allowing a correct second stageprogressively while new bone formation implant placement.takes place(1). Finally, mp3 is indicated for horizontal augmentation (two wall defects) in combinationmp3, a pre-hydrated cortico-cancellous with autogenous bone blocks(4) or with OsteoBiol® Lamina: its cortico-cancellousbone mix with 10% collagen gel, has been composition allows a progressive resorption of osteoclastic type, with in parallel a similardeveloped with this innovative rate of new bone formation(1). These unique properties allow a very good graft volumebiotechnology and is a “ready-to-use” preservation, a healthy new bony tissue and ultimately, a successful implantproduct. rehabilitation. 67
  • 12. Heterologous cortico-cancellous collagenated pre-hydrated bone pastePutty Part of a biopsy showing newly formed bone after treatment with OsteoBiol® Putty. Biopsies were taken 5 weeks after implantation in rabbit maxillae. The smaller granules are totally covered by newly formed bone and seams of osteoblasts are recorded almost at all bone surfaces. Both the marrow spaces and bone are fully nurtured by neovessels. Htx-eosine. Original magnification x20 Source: Histology by Dr Ulf Nannmark, University of Göteborg, Sweden
  • 13. Characteristics | Putty PRODUCTS BONE SUBSTITUTESCHARACTERISTICSPutty is a bone paste with at least 80%micronized heterologous bone(granulometry up to 300 µm) and collagengel (OsteoBiol® Gel 0). It is made with anexclusive process that provides the productwith exceptional malleability and plasticity,making it easy to apply in sockets andperi-implant defects with walls.Thanks to its collagen component, theproduct facilitates blood clotting and thesubsequent invasion of repairing and Tissue of originregenerative cells. Successful grafting Cortico-cancellous heterologous bone mixneeds complete stability of the Tissue collagenbiomaterial: for this reason Putty must be Preserved plus an additional 20% OsteoBiol®used only in cavities able to firmly contain Gel 0 (collagen gel)it. Therefore, Putty must not be grafted in Physical formtwo wall defects or in lateral access sinus Plastic consistency composed of collagen gellift procedures. loaded with 80% micronized bone mixHANDLING Composition 80% granulated mix, 20% collagen gelInject the product and adapt it to defect Granulometrymorphology without compression; any non Up to 300 µmstable residue must be removed before softtissue suture. An Evolution membrane is Re-entry time About 4 monthsrecommended to protect Putty grafted in SEM image showing the mixed sizes OsteoBiol Putty particles which have a granulometry of up to 300 microns ®peri-implant defects. Source: Courtesy of Dr Ulf Nannmark, University of Göteborg, Sweden Packaging Syringe: 3x0.25 cc, 0.5 cc, 3x0.5 cc Product codes HPT09S | 1 Syringe | 0.5 cc | Porcine HPT09E | 1 Syringe | 0.5 cc | Equine HPT35S | 3 Syringe | 3x0.5 cc | Porcine HPT35E | 3 Syringe | 3x0.5 cc | Equine HPT32S | 3 Syringe | 3x0.25 cc | Porcine HPT32E | 3 Syringe | 3x0.25 cc | EquineFenestration grafted with OsteoBiol® Putty. Grafting site protected with OsteoBiol® Evolution membraneSource: Courtesy of Dr Atef Ismail Mohamed, The Bone Institute, Egypt 69
  • 14. Putty Clinical indications POST-EXTRACTIVE OSTEOTOME SCIENTIFIC PUBLICATIONS ON OSTEOBIOL® PUTTY SOCKETS SINUS FLOOR ARCURI C, CECCHETTI F, GERMANO F, MOTTA A, SANTACROCE C AUGMENTATION CLINICAL AND HISTOLOGICAL STUDY OF A XENOGENIC BONE SUBSTITUTE USED AS A FILLER IN POSTEXTRACTIVE ALVEOLUS MINERVA STOMATOLOGICA, 2005 JUN;54(6):351-62 BARONE A, AMERI S, COVANI U IMMEDIATE POSTEXTRACTION IMPLANTS: TREATMENT OF RESIDUAL PERI-IMPLANT DEFECTS. A RETROSPECTIVE ANALYSIS EUROPEAN JOURNAL OF IMPLANT PROSTHODONTICS, 2006, 2: 99-106 CALVO GUIRADO JL, PARDO ZAMORA G, SAEZ YUGUERO MR RIDGE SPLITTING TECHNIQUE IN ATROPHIC ANTERIOR For more information on For more information on MAXILLA WITH IMMEDIATE IMPLANTS, BONE REGENERATION ALVEOLAR REGENERATION CRESTAL ACCESS SINUS LIFT AND IMMEDIATE TEMPORISATION: A CASE REPORT see page 18 see page 30 JOURNAL OF IRISH DENTAL ASSOCIATION, 2007 WINTER; 53(4):187-90 NANNMARK U, AZARMEHR I SHORT COMMUNICATION: COLLAGENATED PERI-IMPLANT CORTICO-CANCELLOUS PORCINE BONE GRAFTS. A STUDY IN LESIONS RABBIT MAXILLARY DEFECTS CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, EPUB 2010 SANTAGATA M, GUARINIELLO L, TARTARO G A MODIFIED EDENTULOUS RIDGE EXPANSION (MERE) TECHNIQUE FOR IMMEDIATE PLACEMENT OF IMPLANTS. A CASE REPORT JOURNAL OF ORAL IMPLANTOLOGY, 2010 JUN 16 For more information on DEHISCENCES AND FENESTRATIONS see page 24 RIDGE SPLIT For more information on HORIZONTAL AUGMENTATION see page 42 Source: Tecnoss® Dental Media Library 70
  • 15. Engineered for peri-implant lesions PRODUCTS BONE SUBSTITUTESCLINICAL INDICATIONS SUMMARY BIBLIOGRAPHYImplantology: versatile alveolar filler to (1) ARCURI C, CECCHETTI F, GERMANO F, MOTTA A,preserve crestal volume(1) and in SANTACROCE C CLINICAL AND HISTOLOGICAL STUDY OF A XENOGENICimmediate post-extractive implants where SUBSTITUTE USED AS A FILLER IN POSTEXTRACTIVE ALVEOLUSit facilitates primary stability; ideal for the MINERVA STOMATOLOGICA, 2005, 54: 351-362.treatment of peri-implantitis and in ridge (2) COVANI U, AMERI S, CRESPI R, BARONE Asplit procedures. PRESERVAZIONE DEL PROCESSO ALVEOLARE CON OSSO ETEROLOGO. CONSIDERAZIONI ISTOLOGICHE ITALIAN ORAL SURGERY, 2004, 3: 17-23In crestal access sinus lift, Putty can beused alone or in association with Gen-Os (3) NANNMARK U, AZARMEHR I SHORT COMMUNICATION: COLLAGENATEDto facilitate insertion. CORTICO-CANCELLOUS PORCINE BONE GRAFTS. A STUDY IN RABBIT MAXILLARY DEFECTS CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, EPUBOral surgery: ideal filler after dental 2010extractions, granulomas, dentigenous (4) BARONE A, AMERI S, COVANI Ucysts. IMMEDIATE POSTEXTRACTION IMPLANTS: TREATMENT OF RESIDUAL PERI-IMPLANT DEFECTS. A RETROSPECTIVECLINICAL INDICATIONS OVERVIEW ANALYSIS EUROPEAN JOURNAL OF IMPLANT PROSTHODONTICS, 2006,The exclusive Tecnoss® manufacturing 2: 99- 106process guarantees an exceptional (5) CALVO GUIRADO JL, PARDO ZAMORA G, SAEZ YUGUERO MR RIDGE SPLITTING TECHNIQUE IN ATROPHIC ANTERIORmalleability and plasticity: furthermore the MAXILLA WITH IMMEDIATE IMPLANTS, BONE REGENERATION AND IMMEDIATE TEMPORISATION: Anew syringe packaging gives Putty CASE REPORTextraordinary handling properties making JOURNAL OF THE IRISH DENTAL ASSOCIATION, 2007, 53: 187-190this product the ideal choice forpost-extractive sockets(1,2), self-contained Peri-implant lesion grafted with OsteoBiol® Putty Source: Tecnoss® Dental Media Library Peri-implant lesion grafded with OsteoBiol® Putty Source: Courtesy of Dr Roberto Rossi, Genova, Italyperi-implant defects and all defects thatpresent a self-contained cavity. immediate post-extractive implants placement, Putty can be injected betweenThanks to the collagen component, Putty the defect walls and the implant,facilitates blood clotting and the guaranteeing a perfect filling of the entiresubsequent invasion of repairing and defect volume(4).regenerative cells. Furthermore, theTecnoss® manufacturing process avoids The product versatility also makes Putty thegranules ceramization, allowing a ideal solution when bone tissue has beenprogressive resorption of the biomaterial lost due to peri- implantitis as long as theand, at the same time, a significant containing walls are present. In fact, thenew-bone formation rate(3). primary condition for gaining a successful regeneration is to achieve the biomaterialPuttys “soft” consistency also guarantees initial stability. Therefore, Putty must bean easy and healthy soft-tissues healing. used only in self contained defects whereThanks to these unique characteristics, the surrounding walls guarantee thisPutty is particularly indicated for condition: for example post-extractiveperi-implant defects regeneration: following sockets and inside the bone crest when ridge-split technique is adopted(5). Peri-implant lesion grafted with OsteoBiol® Putty Source: Tecnoss® Dental Media Library 71
  • 16. Gel 40 Heterologous cortico-cancellous collagenated pre-hydrated bone gel Part of a biopsy showing newly formed bone after treatment with OsteoBiol® Gel 40. Biopsies were taken 5 weeks after implantation in rabbit maxillae. Htx-eosine. Original magnification x20 Source: Histology by Dr Ulf Nannmark, University of Göteborg, Sweden
  • 17. Characteristics | Gel 40 PRODUCTS BONE SUBSTITUTESCHARACTERISTICSCollagen matrix (type I and III) obtainedusing exclusive Tecnoss® process, loadedfor 60% of its volume with micronizedheterologous bone (granulometry up to300 µm). The product is in a gel state attemperatures below 30° C; at highertemperatures the viscosity is reduced andGel 40 can be mixed with hydrosolubleand/or liposoluble drugs. Thanks to itscollagen component, Gel 40 facilitates theformation of primary blood clot and thesubsequent invasion of repairing and Tissue of origin Cortico-cancellous heterologous bone mixregenerative cells; moreover thecortico-cancellous component provides Tissue collagenthe necessary scaffold function. Preserved plus an additional 40% OsteoBiol® Gel 0 (collagen gel)The collagen gel component contained in Physical form OsteoBiol® Gel 40 grafted in a gingival recession caseGel 40 is rapidly and totally resorbed; it is Source: Courtesy of Dr Daniele Cardaropoli, Torino, Italy Collagen gel type I and III loaded with 60% bonealso endowed with exceptional mixanti-inflammatory, eutrophic and Compositioncicatrizing properties. This lipophilia is due 60% granulated mix, 40% collagen gelmainly to a percentage of polyunsaturated Granulometryfatty acids of the oleic-linoleic series (to Up to 300 µmwhich Omega 3 also belongs) directly Re-entry timederived from the raw material. Such About 4 monthscomponents possess a valuable Packagingantioxidant action on the free radicals and Syringe: 0.5 cc, 3x0.5 cctherefore aid tissue regeneration. Product codesHANDLING 05GEL40S | 1 Syringe | 0.5 cc | Porcine 05GEL40E | 1 Syringe | 0.5 cc | EquineThe distinctive characteristics of viscosity 15GEL40S | 3 Syringe | 3x0.5 cc | Porcineand density of Gel 40 facilitate the 15GEL40E | 3 Syringe | 3x0.5 cc | Equinehandling of the product by the operator,providing a glue-like support. If viscosity isexcessive, add a few drops of sterilelukewarm saline and then re-mixthoroughly to obtain the desired density.Placed on site Gel 40 combines withblood, contributing to the fast andcompact formation of primary blood clot. OsteoBiol® Gel 40 pre-hydrated and ready-to-use syringe Source: Tecnoss® Dental Media Library 73
  • 18. Gel 40 Clinical indications INTRABONY SCIENTIFIC PUBLICATIONS ON OSTEOBIOL® GEL 40 DEFECTS AND BARONE A, CORNELINI R, CIAGLIA R, COVANI U GINGIVAL IMPLANT PLACEMENT IN FRESH EXTRACTION SOCKETS AND SIMULTANEOUS OSTEOTOME SINUS FLOOR RECESSIONS ELEVATION: A CASE SERIES INTERNATIONAL JOURNAL OF PERIODONTICS AND RESTORATIVE DENTISTRY, 2008 JUN;28(3):283-9 COVANI U, CORNELINI R, BARONE A BUCCAL BONE AUGMENTATION AROUND IMMEDIATE IMPLANTS WITH AND WITHOUT FLAP ELEVATION: A MODIFIED APPROACH INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL IMPLANTS, 2008 SEP-OCT;23(5):841-6 CARDAROPOLI D, CARDAROPOLI G For more information on HEALING OF GINGIVAL RECESSIONS USING A PERIODONTAL REGENERATION COLLAGEN MEMBRANE WITH A HEMINERALIZED see page 50 XENOGRAFT: A RANDOMIZED CONTROLLED CLINICAL TRIAL INTERNATIONAL JOURNAL OF PERIODONTICS AND RESTORATIVE DENTISTRY, 2009 FEB;29(1):59-67 OSTEOTOME NANNMARK U, AZARMEHR I SINUS FLOOR SHORT COMMUNICATION: COLLAGENATED AUGMENTATION CORTICO-CANCELLOUS PORCINE BONE GRAFTS. A STUDY IN RABBIT MAXILLARY DEFECTS CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, EPUB 2010 PAGLIANI L, ANDERSSON P LANZA M, NAPPO A, VERROCCHI , D, VOLPE S, SENNERBY L A COLLAGENATED PORCINE BONE SUBSTITUTE FOR AUGMENTATION AT NEOSS IMPLANT SITES: A PROSPECTIVE 1-YEAR MULTICENTER CASE SERIES STUDY WITH HISTOLOGY CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2010 OCT 26 EPUB For more information on SANTAGATA M, GUARINIELLO L, RAUSO R, TARTARO G CRESTAL ACCESS SINUS LIFT IMMEDIATE LOADING OF DENTAL IMPLANT AFTER see page 30 SINUS FLOOR ELEVATION WITH OSTEOTOME TECHNIQUE: A CLINICAL REPORT AND PRELIMINARY RADIOGRAPHIC RESULTS JOURNAL OF ORAL IMPLANTOLOGY, 2010 DEC; 36(6): 485-489 Source: Tecnoss® Dental Media Library 74
  • 19. A unique heterologous bone gel PRODUCTS BONE SUBSTITUTES BIBLIOGRAPHY (1) COVANI U, CORNELINI R, BARONE A BUCCAL BONE AUGMENTATION AROUND IMMEDIATE IMPLANTS WITH AND WITHOUT FLAP ELEVATION: A MODIFIED APPROACH THE INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL IMPLANTS, 2008, 23: 841-846 (2) BARONE A, CORNELINI R, CIAGLIA R, COVANI U IMPLANT PLACEMENT IN FRESH EXTRACTION SOCKETS AND SIMULTANEOUS OSTEOTOME SINUS FLOOR ELEVATION: A CASE SERIES INTERNATIONAL JOURNAL OF PERIODONTICS AND RESTORATIVE DENTISTRY, 2008, 28:283-289 (3) CARDAROPOLI D, CARDAROPOLI G Crestal access sinus lift performed with OsteoBiol® Gel 40 HEALING OF GINGIVAL RECESSIONS USING A COLLAGEN Source: Courtesy of Prof Dr Jose Luis Calvo Guirado, Murcia, Spain MEMBRANE WITH A DEMINERALIZED XENOGRAFT: A RANDOMIZED CONTROLLED CLINICAL TRIAL INT J PERIODONTICS RESTORATIVE DENT. 2009 FEB;29(1):59-67 (4) NANNMARK U, AZARMEHR I SHORT COMMUNICATION: COLLAGENATED CORTICO- CANCELLOUS PORCINE BONE GRAFTS. A STUDY IN RABBIT MAXILLARY DEFECTS CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, EPUB 2010Three-wall intrabony defect grafted with OsteoBiol® Gel 40 Intrabony defect grafted with OsteoBiol® Gel 40Source: Tecnoss® Dental Media Library Source: Courtesy of Dr Walter Rao, Pavia, ItalyCLINICAL INDICATIONS SUMMARY defects and, in combination with EvolutionMaxillary sinus lift with crestal access; membranes, for gingival recessions(3).treatment of 3-wall periodontal defects Thanks to the collagen component, Gel 40and gingival recessions; it can also be facilitates blood clotting and theused mixed with OsteoBiol® Gen-Os as subsequent invasion of repairing andgraft stabilizer. regenerative cells.CLINICAL INDICATIONS OVERVIEW Furthermore, the Tecnoss® manufacturingThe exclusive Tecnoss® manufacturing process avoids granules ceramization,process guarantees an exceptional allowing a progressive resorption of themalleability and plasticity(1): furthermore biomaterial and, at the same time, athe syringe packaging gives Gel 40 significant new-bone formation rate(4).extraordinary handling properties makingthis product the ideal choice for crestal Gel 40 “soft” consistency also guaranteesaccess sinus lift(2), deep and narrow an easy and healthy soft-tissues healing.peri-implant defects, three-wall intrabony Crestal access sinus lift with OsteoBiol® Gel 40 Source: Tecnoss® Dental Media Library 75
  • 20. Membranes and barriers OsteoBiol® membranes and barriers MEMBRANES BARRIERS Evolution Special Duo-Teck Derma Lamina Heterologous Heterologous Lyophilised equine Porcine derma Cortical bone pericardium pericardium collagen felt + bone Dried membrane with one Translucent Dried membrane Dried Rigid dried smooth side and one dried covered with membrane lamina, flexible micro-rough side membrane micronized bone after re-hydration Intrabony defect graft protected by OsteoBiol® Special protecting the Schneider OsteoBiol® Duo-Teck grafted OsteoBiol® Derma grafted in lateral sinus wall OsteoBiol® Lamina for the covering of a OsteoBiol® Evolution membrane before grafting Source: Courtesy of Dr Donato Frattini, Legnano, Italy Source: Courtesy of Dr Antonio J. Murillo Rodriguez, horizontally augmented area Source: Courtesy of Dr Roberto Abundo and Dr Source: Courtesy of Dr Donato Frattini, Legnano, Italy For more information on OsteoBiol® Duo-Teck Eibar, Spain Source: Courtesy of Prof Dr Hannes Wachtel and Dr Giuseppe Corrente, Torino, Italy For more information on OsteoBiol® Special see page 91 For more information on OsteoBiol® Derma Tobias Thalmair, Munich, Germany For more information on OsteoBiol® Evolution see page 92 see page 93 For more information on OsteoBiol® Lamina see page 78 see page 82 SEM image showing collagenic matrix of OsteoBiol® membranes Source: Courtesy of Nobil Bio Ricerche, Villafranca d’Asti, Italy
  • 21. PRODUCTS MEMBRANES AND BARRIERSMEMBRANES SIZE THICKNESS ESTIMATED RESORPTION TIME The average reported values are indicative and The average reported values are indicative and The reported values are estimates and purely subject to a variability range depending on the subject to a variability range depending on the indicative: these values can therefore vary depending heterologous origin of the products. composition of the tissues of origin. on the patient and grafting site.Evolution Standard 20x20 30x30 25x35Evolution Fine 20x20 30x30 25x35Special 20x20 30x30Duo-Teck 20x20Derma Standard 30x30 2.00Derma Fine 25x25 0 0.25 0.50 0.75 1.00 0 1 2 3 4 millimeters millimeters months ± 0.1mmBONE BARRIERS SIZE THICKNESS ESTIMATED RE-ENTRY TIME The average reported values are indicative and The average reported values are indicative and The reported values are estimates and purely subject to a variability range depending on the subject to a variability range depending on the indicative: these values can therefore vary depending heterologous origin of the products. composition of the tissues of origin. on the patient and grafting site.Lamina Fine 25x25 20x40 25x35Curved Lamina 35x35 curvedLamina Standard 30x30 2-4 8 0 0.25 0.50 0.75 1.00 3 4 5 6 7 millimeters months millimetersSource: Tecnoss® s.r.l. ± 0.1mm 77
  • 22. Evolution Heterologous pericardium SEM image showing collagenic matrix of OsteoBiol® Evolution Source: Courtesy of Nobil Bio Ricerche, Villafranca d’Asti, Italy
  • 23. Characteristics | Evolution PRODUCTS MEMBRANES AND BARRIERSCHARACTERISTICSObtained from mesenchymal tissue(heterologous pericardium) the Evolutionmembrane is completely resorbable. Itsstructure is made of dense collagen fibersof high consistency and of extraordinaryresistance that offer the specialist surgeon:>> the maximum adaptability to bonetissue and soft tissues>> an easy and secure suturability tonearby tissues Tissue of origin>> the best membrane/bone and Heterologous pericardiummembrane/periosteum interface Tissue collagen>> stability and prolonged protection of Preservedthe underlying graft Physical form Dried membrane with one smooth side and oneHANDLING micro-rough side Clinical appication of OsteoBiol® Evolution membrane, stabilizing and protecting the grafting siteMembrane can be shaped with sterile Source: Courtesy of Dr Roberto Cocchetto, Zevio, Italy Compositionscissors until the desired size is reached; it 100% pericardiummust then be rehydrated with lukewarm Thicknessphysiological solution. Fine: 0.4 mm (±0.1 mm) Standard: 0.6 mm (±0.1 mm)Once it acquires the desired plasticity, itmust be adapted to the grafting site. Estimated resorption time Fine: about 3 monthsN.B.: in case of accidental exposure, the Standard: about 4 monthsdense collagenic matrix of Evolution Packagingprotects the graft from infection; the 20x20 mm, 30x30 mm, 25x35 mm (oval)membrane itself will also not be infected, Product codesallowing second intention healing. EV02LLE | 20x20 mm | Fine | Equine EV02HHE | 20x20 mm | Standard | Equine EV03LLE | 30x30 mm | Fine | Equine EV03HHE | 30x30 mm | Standard | Equine EVOLLE | 25x35 mm (oval) | Fine | Equine EVOHHE | 25x35 mm (oval) | Standard | Equine OsteoBiol® Evolution membrane Source: Tecnoss® Dental Media Library 79
  • 24. Evolution Clinical indications MAXILLARY PERI-IMPLANT SCIENTIFIC PUBLICATIONS ON OSTEOBIOL® EVOLUTION SINUS FLOOR DEFECTS BARONE A, CRESPI R, ALDINI NN, FINI M, GIARDINO R, COVANI U AUGMENTATION MAXILLARY SINUS AUGMENTATION: HISTOLOGIC AND HISTOMORPHOMETRIC ANALYSIS INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL IMPLANTS, 2005 JUL-AUG;20(4):519-25 BARONE A, AMERI S, COVANI U IMMEDIATE POSTEXTRACTION IMPLANTS: TREATMENT OF RESIDUAL PERI-IMPLANT DEFECTS. A RETROSPECTIVE ANALYSIS EUROPEAN JOURNAL OF IMPLANT PROSTHODONTICS, 2006, 2: 99-106 BARONE A, SANTINI S, SBORDONE L, CRESPI R, COVANI U A CLINICAL STUDY OF THE OUTCOMES AND COMPLICATIONS ASSOCIATED WITH MAXILLARY SINUS AUGMENTATION INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL IMPLANTS, For more information on For more information on 2006 JAN-FEB;21(1):81-5 LATERAL ACCESS SINUS LIFT DEHISCENCES AND FENESTRATIONS COVANI U, BARONE A, CORNELINI R, CRESPI R see page 36 see page 24 CLINICAL OUTCOME OF IMPLANTS PLACED IMMEDIATELY AFTER IMPLANT REMOVAL JOURNAL OF PERIODONTOLOGY, 2006 APR;77(4):722-7 COVANI U, CORNELINI R, BARONE A INTRABONY POST-EXTRACTIVE BUCCAL BONE AUGMENTATION AROUND IMMEDIATE IMPLANTS DEFECTS SOCKETS WITH AND WITHOUT FLAP ELEVATION: A MODIFIED APPROACH INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL IMPLANTS, 2008 SEP-OCT;23(5):841-6 CARDAROPOLI D, CARDAROPOLI G PRESERVATION OF THE POSTEXTRACTION ALVEOLAR RIDGE: A CLINICAL AND HISTOLOGIC STUDY INTERNATIONAL JOURNAL OF PERIODONTICS AND RESTORATIVE DENTISTRY, 2008 OCT;28(5):469-77 NANNMARK U, SENNERBY L THE BONE TISSUE RESPONSES TO PREHYDRATED AND COLLAGENATED CORTICO-CANCELLOUS PORCINE BONE GRAFTS: A STUDY IN RABBIT MAXILLARY DEFECTS CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2008 DEC;10(4):264-70. EPUB 2008 JAN 30 For more information on For more information on SCARANO A, PIATTELLI A, PERROTTI V, MANZON L, IEZZI G PERIODONTAL REGENERATION ALVEOLAR REGENERATION MAXILLARY SINUS AUGMENTATION IN HUMANS USING see page 50 see page 18 CORTICAL PORCINE BONE: A HISTOLOGICAL AND HISTOMORPHOMETRICAL EVALUATION AFTER 4 AND 6 MONTHS CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2009 CARDAROPOLI D, CARDAROPOLI G TWO-WALL INLAY HEALING OF GINGIVAL RECESSIONS USING A COLLAGEN MEMBRANE WITH A HEMINERALIZED XENOGRAFT: A DEFECTS TECHNIQUE RANDOMIZED CONTROLLED CLINICAL TRIAL INTERNATIONAL JOURNAL OF PERIODONTICS AND RESTORATIVE DENTISTRY, 2009 FEB;29(1):59-67 SLOTTE C, LINDFORS N, NANNMARK U SURGICAL RECONSTRUCTION OF PERI-IMPLANT BONE DEFECTS WITH PREHYDRATED AND COLLAGENATED PORCINE BONE AND COLLAGEN BARRIERS: CASE PRESENTATIONS CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH 2011 DEC 6, EPUB AHEAD OF PRINT BARONE A, RICCI M, GRASSI RF, NANNMARK U, QUARANTA A, COVANI U A 6-MONTH HISTOLOGICAL ANALYSIS ON MAXILLARY SINUS AUGMENTATION WITH AND WITHOUT USE OF COLLAGEN MEMBRANES OVER THE OSTEOTOMY WINDOW: RANDOMIZED CLINICAL TRIAL CLINICAL ORAL IMPLANTS RESEARCH 2011 DEC 12, EPUB AHEAD OF PRINT For more information on For more information on HORIZONTAL AUGMENTATION VERTICAL AUGMENTATION BARONE A, RICCI M, CALVO GUIRADO JL, COVANI U see page 42 BONE REMODELLING AFTER REGENERATIVE PROCEDURES AROUND see page 42 IMPLANTS PLACED IN FRESH EXTRACTION SOCKETS: AN EXPERIMENTAL STUDY IN BEAGLE DOGS CLINICAL ORAL IMPLANTS RESEARCH, IN PRESS Source: Tecnoss® Dental Media Library 80
  • 25. The natural Evolution of collagen membranes PRODUCTS MEMBRANES AND BARRIERSCLINICAL INDICATIONS SUMMARY The dense collagenic matrix of Evolution BIBLIOGRAPHYOral surgery and traumatology: the protects the graft from infection in case of (1) NANNMARK U, SENNERBY Lstandard model is always recommended accidental exposure: the membrane itself THE BONE TISSUE RESPONSES TO PREHYDRATED ANDin case of large regenerations with risks of will also not be infected, allowing second COLLAGENATED CORTICO-CANCELLOUS PORCINE BONE GRAFTS. A STUDY IN RABBIT MAXILLARY DEFECTSexposure. intention healing. CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2008, 10: 264-270Implantology: ideal for covering This property is particularly important in (2) CARDAROPOLI D, CARDAROPOLI Gantrostomy and for protection of two wall case of regeneration of large posterior PRESERVATION OF THE POSTEXTRACTION ALVEOLAR RIDGE: A CLINICAL AND HISTOLOGIC STUDYdefects graft. sockets, when flaps cannot completely THE INTERNATIONAL JOURNAL OF PERIODONTICS AND RESTORATIVE DENTISTRY, 2008, 28: 469-477 cover the graft(2).Periodontology: protection of grafted (3) BARONE A, CRESPI R, NICOLI ALDINI N, FINI M, GIARDINO R,intrabony defects when flaps suture In lateral access sinus lift Evolution COVANI U MAXILLARY SINUS AUGMENTATION: HISTOLOGIC ANDpresents risks of exposure and as space membranes are indicated to cover HISTOMORPHOMETRIC ANALYSIS THE INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIALmaker in gingival recessions (fine model). antrostomy (standard model)(3,4,5) and to IMPLANTS, 2005, 20: 519-525 protect the sinus membrane from cutting (4) BARONE A, MARCONCINI S, SANTINI S, COVANI UBesides an eutrophic effect, Evolution risk due to graft pressure (fine model or OSTEOTOMY AND MEMBRANE ELEVATION DURING THEmembranes provide grafting site OsteoBiol® Special, see page 92). MAXILLARY SINUS AUGMENTATION PROCEDURE. A COMPARATIVE STUDY: PIEZOELECTRIC DEVICE VS.stabilization as well as long lasting CONVENTIONAL ROTATIVE INSTRUMENTSprotection against external agents. Evolution is also ideal to protect CLINICAL ORAL IMPLANTS RESEARCH, 2008, 19: 511-515 peri-implant regenerations(6) and (5) BARONE A, SANTINI S, SBORDONE L, CRESPI R, COVANI UCLINICAL INDICATIONS OVERVIEW A CLINICAL STUDY OF THE OUTCOMES AND periodontal grafts. COMPLICATIONS ASSOCIATED WITH MAXILLARY SINUSEvolution is obtained from mesenchymal AUGMENTATIONtissue (heterologous pericardium) and is Finally Evolution fine has been successfully THE INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL IMPLANTS, 2006, 26: 81-85completely resorbable. used in combination with OsteoBiol ® (6) BARONE A, AMERI S, COVANI U Gel 40 for the treatment of gingival IMMEDIATE POSTEXTRACTION IMPLANTS: TREATMENT OFExperimental studies have shown recessions(7). RESIDUAL PERI-IMPLANT DEFECTS. A RETROSPECTIVE ANALYSIShistological evidence of the prolonged EUROPEAN JOURNAL OF IMPLANT PROSTHODONTICS, 2006, 2: 99-106barrier effect of this membrane, which (7) CARDAROPOLI D, CARDAROPOLI Glasts at least eight weeks(1). HEALING OF GINGIVAL RECESSIONS USING A COLLAGEN MEMBRANE WITH A HEMINERALIZED XENOGRAFT: A Grafting site protected with OsteoBiol® Evolution RANDOMIZED CONTROLLED CLINICAL TRIAL Source: Courtesy of Dr Roberto Rossi, Genova, Italy INT J PERIODONTICS RESTORATIVE DENT. 2009 FEB;29(1):59-67Grafting site stabilized with OsteoBiol® Evolution Intrabony defect graft protected by OsteoBiol® Evolution Intrabony defect graft covered by OsteoBiol® EvolutionSource: Courtesy of Dr Francesco Vedove, Bassano del Grappa, Italy Source: Courtesy of Dr R Abundo and Dr G Corrente, Torino, Italy Source: Courtesy of Dr Roberto Rossi, Genova, Italy 81
  • 26. Lamina Heterologous cortical bone LM image of an OsteoBiol® Lamina hydrated with blood: vascularisation enhanced by the presence of the original vascular canals Source: Courtesy of Prof Ulf Nannmark, Göteborg University, Sweden
  • 27. Characteristics | Lamina PRODUCTS MEMBRANES AND BARRIERSCHARACTERISTICS OsteoBiol® Curved Lamina has a OsteoBiol® Curved Lamina should not beOsteoBiol® Lamina is made of cortical semi-rigid consistency and can be grafted hydrated but can also be shaped withbone of heterologous origin produced with without hydration, provided that it is sterile scissors, and must be fixated withan exclusive Tecnoss® process that avoids previously shaped to fit the defect osteosynthesis screws. In case of exposure,the ceramization of hydroxyapatite morphology. Lamina should only be removed if there iscrystals, thus accelerating physiological HANDLING a clear suprainfection, because itsresorption. consistency is such as to allow it to achieve OsteoBiol® Lamina can be shaped with a complete second intention healing of theAfter a process of superficial sterile scissors until the desired size is wound.decalcification, it acquires an elastic reached, then it must be hydrated for 5/10consistency, nevertheless maintaining the minutes in sterile physiological solution.typical compactness of the bone tissue Once it acquires the desired plasticity, itfrom which it originates; the margins are must be adapted to the grafting site; it Tissue of originsoft in order not to cause micro traumas to Cortical bone should always be immobilized either withthe surrounding tissues. titanium microscrews or sutured (fine Tissue collagen model) directly to the surrounding tissues Preserved with a triangular section non-traumatic Physical form needle. Rigid dried lamina, flexible after re-hydration Composition 100% cortical bone Thickness Fine: 0.4-0.6 mm Medium Curved: 0.8-1.0 mm Standard: 2-4 mm Estimated re-entry time Fine: about 5 months Medium Curved: about 6 months Standard: about 8 months Packaging Fine: 25x25 mm, 20x40 mm, 25x35 mm (oval) Medium Curved: 35x35 mm (curved) Standard: 30x30 mm Product codes LS25FS | 25x25x(0.4-0.6) mm | Fine | Porcine LS25FE | 25x25x(0.4-0.6) mm | Fine | Equine LS24FS | 20x40x(0.4-0.6) mm | Fine | Porcine LS24FE | 20x40x(0.4-0.6) mm | Fine | Equine LS23FS | 25x35x(0.4-0.6) mm (oval) | Fine | Porcine LS23FE | 25x35x(0.4-0.6) mm (oval) | Fine | Equine LS10HS | 35x35x(0.8-1.0) mm | Curved | Porcine LS10HE | 35x35x(0.8-1.0) mm | Curved | Equine LS03SS | 30x30x(2.0-4.0) mm | Standard | PorcineOsteoBiol® Curved Lamina OsteoBiol® LaminaSource: Tecnoss® Dental Media Library Source: Tecnoss® Dental Media Library LS03SE | 30x30x(2.0-4.0) mm | Standard | Equine 83
  • 28. Lamina Clinical indications TWO-WALL SCIENTIFIC PUBLICATIONS ON OSTEOBIOL® LAMINA DEFECTS RINNA C, UNGARI C, SALTAREL A, CASSONI A, REALE G ORBITAL FLOOR RESTORATION JOURNAL OF CRANIOFACIAL SURGERY, 2005 NOV;16(6):968-72 SCARANO A, PIATTELLI M, CARINCI F, PERROTTI V REMOVAL, AFTER 7 YEARS, OF AN IMPLANT DISPLACED INTO THE MAXILLARY SINUS. A CLINICAL AND HISTOLOGIC CASE REPORT JOURNAL OF OSSEOINTEGRATION, 2009 GRENGA PL, REALE G, COFONE C, MEDURI A, CERUTI P GRENGA R , HESS AREA RATIO AND DIPLOPIA: EVALUATION OF 30 PATIENTS UNDERGOING SURGICAL REPAIR FOR ORBITAL BLOW-OUT FRACTURE For more information on OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2009; 25(2) HORIZONTAL AUGMENTATION RINNA C, REALE G, FORESTA E, MUSTAZZA MC see page 42 MEDIAL ORBITAL WALL RECONSTRUCTION WITH SWINE BONE CORTEX THE JOURNAL OF CRANIOFACIAL SURGERY, 2009; 20(3) PAGLIANI L, ANDERSSON P LANZA M, NAPPO A, VERROCCHI D, , VOLPE S, SENNERBY L A COLLAGENATED PORCINE BONE SUBSTITUTE FOR AUGMENTATION AT NEOSS IMPLANT SITES: A PROSPECTIVE 1-YEAR MULTICENTER CASE SERIES STUDY WITH HISTOLOGY CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2010 OCT 26 EPUB HINZE M, VRIELINCK L, THALMAIR T, WACHTEL H, BOLZ W ZYGOMATIC IMPLANT PLACEMENT IN CONJUCTION WITH SINUS BONE GRAFTING: THE "EXTENDED SINUS ELEVATION TECHNIQUE". A CASE-COHORT STUDY ORAL AND CRANIOFACIAL TISSUE ENGINEERING 2011; 1:188-197 Source: Tecnoss® Dental Media Library 84
  • 29. A unique cortical bone barrier PRODUCTS MEMBRANES AND BARRIERSCLINICAL INDICATIONS SUMMARY BIBLIOGRAPHYOral surgery and Traumatology: (1) PAGLIANI L, ANDERSSON P LANZA M, NAPPO A, VERROCCHI ,stabilization and protection of large D, VOLPE S, SENNERBY L A COLLAGENATED PORCINE BONE SUBSTITUTE FORregenerations with risks of exposure, AUGMENTATION AT NEOSS IMPLANT SITES: Awhere it perfectly adapts itself both to the PROSPECTIVE 1-YEAR MULTICENTER CASE SERIES STUDY WITH HISTOLOGYunderlying bone and to the soft tissues. CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH 2010 OCT 26, EPUBImplantology: ideal for protection and (2) RINNA C, UNGARI C, SALTAREL A, CASSONI A, REALE Gstabilization of two-wall defect grafts or CLINICAL NOTES. ORBITAL FLOOR RESTORATION THE JOURNAL OF CRANIOFACIAL SURGERY, 2005, 16: 968-972peri-implant regenerations in esthetic (3) RINNA C, REALE G, FORESTA E, MUSTAZZA MCareas. Fine model is also indicated for MEDIAL ORBITAL WALL RECONSTRUCTION WITH SWINE BONE CORTEXcovering antrostomy. THE JOURNAL OF CRANIOFACIAL SURGERY, 2009; 20(3)Fixtation of OsteoBiol® cortical Lamina with titaniun pins Horizontal defect grafted with OsteoBiol® Lamina stabilized with a titanium post and osteosynthesis screwsSource: Courtesy of Prof Dr Hannes Wachtel and Dr Tobias Thalmair, Source: Courtesy of Dr Luca Giovanni Maria Pagliani, Milano, ItalyMunich, Germany CLINICAL INDICATIONS OVERVIEW Cortical Laminae are made of cortical bone of heterologous origin which undergoes a process of superficial decalcification, nevertheless maintaining the typical consistency of the bone tissue from which it originates. The Fine model after hydration become flexible and can be adapted to the defect morphology creating, once fixated with osteosynthesis screws, a semi-rigid covering to the underlying graft(1). This property is particularly useful when it is necessary to obtain a space making effect in esthetic areas, as well as in horizontal augmentation of two wall defects. Lamina can also be used for orbital floor restoration(2,3). The Curved Lamina has a 0.8-1.0 mm thickness and can be directly grafted without hydration: it is particularly indicated in association with OsteoBiol® mp3 for regenerationClinical application of OsteoBiol® Curved Lamina of ridges with compromised cortical plate.in horizontal augmentationSource: Courtesy of Dr Guido Miele, Salzano, Italy 85
  • 30. Specific products Specially engineered solutions for specific clinical indications SEM image of OsteoBiol® cancellous block trabeculae Source: Courtesy of Dr Ulf Nannmark, University of Göteborg, Sweden
  • 31. OsteoBiol® Sp-Block PRODUCTS SPECIFIC PRODUCTSCollagenated cancellous blocks SCIENTIFIC PUBLICATIONS ON OSTEOBIOL® SP-BLOCK SCARANO A, CARINCI F, ASSENZA B, PIATTELLI M, MURMURA G, PIATTELLI ACHARACTERISTICS HANDLING VERTICAL RIDGE AUGMENTATION OF ATROPHIC POSTERIOR MANDIBLE USING AN INLAY TECHNIQUE WITH A XENOGRAFTCancellous block of xenogenic bone Sp-Block must be hydrated before use for WITHOUT MINISCREWS AND MINIPLATES: CASE SERIES CLINICAL ORAL IMPLANTS RESEARCH, 2011 OCT; 22(10):1125-30produced with an exclusive Tecnoss® 5/10 minutes with sterile lukewarmprocess which avoids ceramization of the physiological solution or with antibiotics.hydroxyapatite crystals, thus accelerating Afterwards, it can be adapted to thephysiological resorption. Sp-Block receiving site which must be accuratelysupports new bone formation: thanks to its decorticated in order to guaranteerigid consistency it is able to maintain in maximum contact; the block must alwaystime the original graft volume, which is be fixed with osteosynthesis microscrewsparticularly important in case of large and should be protected with a resorbableregenerations. Moreover, its collagen Tissue of origin barrier (Evolution membrane). Cancellous blockcontent facilitates blood clotting and thesubsequent invasion of regenerative and Tissue collagenrepairing cells, favoring restitutio ad Preservedintegrum of missing bone. OsteoBiol® Sp-Block hydrated with patient’s blood Physical form Source: Tecnoss® Dental Media Library Rigid dried block Composition 100% cancellous bone Re-entry time About 8 months, variable depending on characteristics and irroration grade of grafting site and on clinical conditions of patient Packaging Sterile blister Product codes BN0E | 1 Blister | 10x10x10 mm | Equine Inlay technique with OsteoBiol® Sp-Block Source: Courtesy of Dr Pietro Felice, Bologna, Italy BN1E | 1 Blister | 10x10x20 mm | Equine BN2E | 1 Blister | 10x20x20 mm | Equine BN8E | 1 Blister | 35x10x5 mm | EquineSEM image of OsteoBiol® cancellous block OsteoBiol® Sp-Block grafted with inlay techniqueSource: Courtesy of Dr Ulf Nannmark, University of Göteborg, Sweden Source: Tecnoss® Dental Media Library 87
  • 32. OsteoBiol® Dual-BlockCollagenated cancellous blocksCHARACTERISTICS Afterwards, the block can be adapted toDual-Block is a cortico-cancellous block of the receiving site which must be accuratelyxenogenic bone with osteoconductive decorticated in order to guaranteecharacteristics. It can be used when the maximum contact and the block should beregeneration of big volumes is needed: always fixed with osteosynthesisthanks to the collagen content that microscrews.promotes blood clotting and migration of Dual-Block is indicated for heavilyregenerative and repairing cells, the graft resorbed maxilla horizontal augmentation.is gradually resorbed, while new bone is Whatever is the applied technique, it isproduced by osteoblasts. recommended to fill the gaps around the Tissue of originHANDLING block with a biomaterial in granules to Cortico-cancellous boneDual-Block must be hydrated before use achieve the desired volume and contour of OsteoBiol® Dual-Block Tissue collagenfor 5/10 minutes with sterile lukewarm the augmented recipient site. Source: Tecnoss® Dental Media Library Preservedphysiological solution or with antibiotics. Physical form Rigid dried block Composition 100% cancellous bone Re-entry time About 8 months, variable depending on characteristics and irroration grade of grafting site and on clinical conditions of patient Packaging Sterile blister Product codes OsteoBiol® Dual-Block properly shaped, fixed with an osteosynthesis screw and surrounded by bone granules STS7S | 20x15x5 mm | Porcine curved Source: Courtesy of Dr Roberto Rossi, Genova, Italy STN4B | 20x15x5 mm | Bovine STN5B | 20x10x5 mm | Bovine curved STN6B | 20x20x5 mm | Bovine curvedSEM image of OsteoBiol® Dual-Block OsteoBiol® Dual-Block grafted with inlay techniqueSource: Politecnico di Torino, Italy Source: Tecnoss® Dental Media Library88
  • 33. Nanocrystalline hydroxyapatite PRODUCTS SPECIFIC PRODUCTSOsteoBiol® ApatosCHARACTERISTICS HANDLING SCIENTIFIC PUBLICATIONS ON OSTEOBIOL® APATOS BARONE A, AMERI S, COVANI UApatos is a biomaterial of heterologous Apatos must always be hydrated and IMMEDIATE POSTEXTRACTION IMPLANTS: TREATMENT OForigin with characteristics similar to thoroughly mixed with a few drops of RESIDUAL PERI-IMPLANT DEFECTS. A RETROSPECTIVE ANALYSISmineralized human bone; it can therefore sterile saline; it can also be mixed with EUROPEAN JOURNAL OF IMPLANT PROSTHODONTICS, 2006, 2: 99-106be used as alternative to autologous bone. patient’s blood. Finally it can be mixed ifThe natural microporous consistency of necessary with the drug selected for ORSINI G, SCARANO A, PIATTELLI M, PICCIRILLI M, CAPUTI S, PIATTELLI AApatos facilitates the formation of new surgery; the mixture thus obtained should HISTOLOGIC AND ULTRASTRUCTURAL ANALYSIS OF REGENERATED BONE IN MAXILLARY SINUS AUGMENTATIONbone tissue in bone defect area, be positioned with a sterile spatula or USING A PORCINE BONE-DERIVED BIOMATERIALaccelerating the process. Apatos syringe for biomaterials. JOURNAL OF PERIODONTOLOGY, 2006 DEC;77(12):1984-90nanocrystalline hydroxyapatite is available CLINICAL INDICATIONS TRUBIANI O, SCARANO A, ORSINI G, DI IORIO D, DARCANGELO C, PICCIRILLI M, SIGISMONDO M, CAPUTI Sin cancellous, cortical and mixed granules. THE PERFORMANCE OF HUMAN PERIODONTAL LIGAMENT Tissue of origin Oral surgery: granulomas, dentigenous MESENCHYMAL STEM CELLS ON XENOGENIC BIOMATERIALS Apatos Mix: Cortico-cancellous heterologous INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND bone mix cysts and ridge split. PHARMACOLOGY, 2007 JAN-MAR;20(1 SUPPL 1):87-91 Apatos Cortical: Heterologous cortical bone SCARANO A, PIATTELLI A, ASSENZA B, QUARANTA A, Implantology: universal filler used in PERROTTI V, PIATTELLI M, IEZZI G Tissue collagen treatment of dehiscences and PORCINE BONE USED IN SINUS AUGMENTATION Degraded PROCEDURES: A 5-YEAR RETROSPECTIVE CLINICAL peri-implantitis, two wall defects, lateral EVALUATION Physical form and crestal access sinus lift. In particular JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2010 AUG; Radiopaque granules of mineral hydroxyapatite 68(8):1869-73 Apatos Cortical is characterized by a very Composition SCARANO A, PIATTELLI A, PERROTTI V, MANZON L, IEZZI G long resorption time, guaranteeing MAXILLARY SINUS AUGMENTATION IN HUMANS USING Apatos Mix: 100% cortico-cancellous mix optimal preservation of the graft volume. CORTICAL PORCINE BONE: A HISTOLOGICAL AND Apatos Cortical: 100% cortical bone HISTOMORPHOMETRICAL EVALUATION AFTER 4 AND 6 MONTHS When needed, Apatos graft can be CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 2011 Granulometry protected with OsteoBiol® Evolution MAR; 13(1):13-18 600-1000 µm membrane or soft cortical Lamina. IEZZI G, DEGIDI M, PIATTELLI A, MANGANO C, SCARANO A, SHIBLI JA, PERROTTI V Re-entry time COMPARATIVE HISTOLOGICAL RESULTS OF DIFFERENT About 5 months BIOMATERIALS USED IN SINUS AUGMENTATION PROCEDURES: A HUMAN STUDY AT 6 MONTHS 2011 NOV 2, EPUB AHEAD OF PRINT Packaging Mix | Vial: 0.5 g, 1.0 g, 2.0 g Cortical | Vial: 0.5 g, 1.0 g Product codes Mix | A1005FS | 1 Vial | 0.5 g | Porcine Mix | A1005FE | 1 Vial | 0.5 g | Equine Mix | A1010FS | 1 Vial | 1.0 g | Porcine Mix | A1010FE | 1 Vial | 1.0 g | Equine Mix | A1020FS | 1 Vial | 2.0 g | Porcine Mix | A1020FE | 1 Vial | 2.0 g | Equine Cortical | AC1005FS | 1 Vial | 0.5 g | Porcine Cortical | AC1010FS | 1 Vial | 1.0 g | PorcineOsteoBiol® Apatos grafted in a large intrabony defect OsteoBiol® Apatos grafted in a horizontal defect SEM images of OsteoBiol® Apatos, cancellous granulesSource: Courtesy of Dr Roberto Rossi, Genova, Italy Source: Courtesy of Dr Roberto Rossi, Genova, Italy Source: Courtesy of Dr Ulf Nannmark, University of Göteborg, Sweden 89
  • 34. Engineered for haemorrhagic patientsOsteoBiol® TabletCHARACTERISTICS people with heart disease treated with Due to this plasticity, TabletThanks to its composition (micronized anticoagulants, people with low platelet antihaemorrhagic blocks are not resistantheterologous bone granules aggregated counts): in these cases, the block acts as a to loading and compression of graftingwith collagen), besides functioning as a uniform sealant of the cavity walls even sites: these conditions must therefore besocket filling material, OsteoBiol® Tablet without stitching the flaps. avoided. If necessary, proceed with suturecan also provide an immediate and constant HANDLING of the alveolar margins.anti-inflammatory and antihaemorrhagic CLINICAL INDICATIONS After debridement of the receiving site,action. directly place the block in the bone cavity Traumatology, Dentistry and wherever fastTablet can thus be considered the first to be filled. Once soaked with blood, its and prolonged antihaemorrhagic action ischoice material after dental extractions plastic consistency allows a perfect needed; Tablet provides also a scaffold Tissue of originand oral surgery in subjects with adaptation to the post-extractive cavity. function in order to avoid the collapse of Cortico-cancellous heterologous bone mixhaemorrhagic predisposition (diabetics, the alveolar walls after dental extractions, Tissue collagen with consequent both vertical and Preserved horizontal bone loss. Physical form Friable dried block Composition 100% bone mix Granulometry Up to 300 µm Re-entry time About 4 months Packaging 6pcs. 10x10x10 mm Product codes BLE10S | 6 Blister | 10x10x10 mm | Porcine BLE10E | 6 Blister | 10x10x10 mm | EquineHaemorrhagic post-extractive socketSource: Courtesy of Prof Dr Claudio Arcuri, Roma, Italy90
  • 35. Granules-coated collagen felt PRODUCTS SPECIFIC PRODUCTSOsteoBiol® Duo-TeckCHARACTERISTICS HANDLING CLINICAL INDICATIONSMade of lyophilized collagen of equine Duo-Teck must be rehydrated with Oral Surgery and Implantology:origin, biocompatible and quickly lukewarm physiological solution. Duo-Teck is indicated in all those casesresorbable. where a “soft” separation between tissues Once it acquires the desired plasticity, it of different consistency is necessary.Duo-Teck differs from other membranes as can be easily placed it in the grafting siteit is coated on one side with a film of with the micronized bone film side in Duo-Teck can be used to protect themicronized bone, also of equine origin: contact with graft and the smooth side in maxillary sinus membrane in lateral accessthis coating increases its consistency and contact with soft tissues: this allows a sinus floor augmentation procedure, instability, allowing good protection of grafts perfect adhesion to the tissue around bone order to avoid accidental lesions causedtogether with a correct repositioning of soft defect. by grafting material. It can be also used for Tissue of origintissues. closure of antrostomy, before replacement Equine lyophilised collagen felt and equine bone of the muco-gingival flap. Tissue collagen Preserved Physical form Dried membrane covered with micronized bone Composition Collagen felt and bone granules Granulometry Up to 300 µm Thickness About 1 mm Estimated resorption time About 15 days Packaging 20x20 mm Product codes DT020 | 1 Blister | 20x20 mm | EquineOsteoBiol® Duo-Teck grafted SEM image of OsteoBiol® Duo-Teck OsteoBiol® Duo-Teck positioned to help guided tissueSource: Courtesy of Dr Donato Frattini, Legnano, Italy Source: Politecnico di Torino, Italy regeneration Source: Courtesy of Dr Atef Ismail Mohamed, Cairo, Egypt 91
  • 36. Engineered to protect hard tissue grafts and soft tissuesOsteoBiol® SpecialCHARACTERISTICS HANDLING CLINICAL INDICATIONSObtained from extra fine mesenchymal Membrane can be shaped with sterile Periodontology: the Special membranetissues (pericardium of heterologous scissors until the desired size is reached; it can be used as a separator of bone andorigin) using an exclusive Tecnoss® must then be rehydrated with lukewarm soft tissues in treatment of gingivalprocess, the dried Special membranes are physiological solution. Once it acquires the recessions.completely resorbable. desired plasticity, it must be adapted to the Implantology: protection of the sinus grafting site. It is recommended to prepareOnce hydrated, they become translucent membrane before insertion of grafting a pocket with an elevator in order toand flexible, guiding the growth of material, closing of sinus membrane stabilize the membrane in the site afterepithelium and preventing its invagination: perforations, protection of grafts placed in stitching the flaps. If this is not possible, thetheir action favors therefore an optimal post-extractive sockets. membrane can be stabilized with envelope Tissue of originregeneration of the underlying bone tissue. Heterologous pericardium sutures which bridle it with the gingival flaps. Tissue collagen Preserved Physical form Translucent dried membrane Composition 100% pericardium Thickness Extra-fine: 0.2 mm Resorption time About 40 days Packaging 20x20 mm, 30x30 mm Product codes EM02LS | 1 Blister | 20x20 mm | Porcine EM02LE | 1 Blister | 20x20 mm | Equine EM03LS | 1 Blister | 30x30 mm | Porcine EM03LE | 1 Blister | 30x30 mm | EquineSEM images of OsteoBiol® Special OsteoBiol® Special protecting the Schneider membraneSource: Courtesy of Nobil Bio Ricerche, Villafranca d’Asti, Italy before grafting Source: Courtesy of Dr Donato Frattini, Legnano, Italy92
  • 37. Porcine derma PRODUCTS SPECIFIC PRODUCTSOsteoBiol® DermaCHARACTERISTICS HANDLING If this is not possible, the membrane canObtained from derma of porcine origin, Derma membrane can be shaped with be stitched with envelope sutures whichusing an exclusive Tecnoss® process, scissors until the desired size is reached; bridle it with the gingival flaps.Derma membranes are completely then it must be hydrated for 15 minutes in N.B.: if Derma membrane, for any reason,gradually resorbable. sterile lukewarm physiological solution. shows dehiscences (for example in theTheir strong consistency and resistance Once it acquires the desired plasticity, it secondary tearing of flaps) it mustallow a perfect stabilization and a must be adapted to the grafting site. It is absolutely not be removed, because itsprolonged protection of underlying graft in always recommendable to prepare a plasticity and consistency is such as tolarge regeneration procedures, together pocket with an elevator in order to stabilize allow it to achieve a complete secondwith a strong barrier action to guide the the membrane in the site after stitching the intention healing of the wound, because of Tissue of origingrowth of epithelium and preventing its flaps. the physiological sliding of the flaps. Porcine dermainvagination. CLINICAL INDICATIONS Tissue collagen Oral Surgery and Traumatology: Preserved stabilization and protection of large Physical form regenerations with risk of exposure. Dried membrane Implantology: protection of two wall Composition 100% derma defects graft, soft tissue augumentation. Thickness Periodontology: space making below Fine: 1.0 mm thin biotype tissues (fine model). Standard: 2.0 mm Estimated resorption time Fine: about 3 months Standard: about 4 months Packaging Fine: 25x25 mm Standard: 30x30 mm Product codes ED25FS | 1 Blister | Fine | 25x25x1 mm | Porcine ED03SS | 1 Blister | Std | 30x30x2 mm | Porcine OsteoBiol® Derma grafted in a case of horizontalOsteoBiol® Derma grafted to promote guided tissue regeneration augmentationSource: Courtesy of Dr Juan M. Aragoneses Lamas, Madrid, Spain Source: Courtesy of Dr Antonio J. Murillo Rodriguez, Eibar, Spain 93
  • 38. Live surgery courses
  • 39. Advanced concepts in implant dentistry. Treatment of Complex Cases: EDUCATION LIVE SURGERY COURSESimplification, Reproducibility, ReliabilityABSTRACT PROGRAM LECTURERS LocationA unique experience giving the participants an Thursday and Friday: live surgeries of complex Dr. Patrick Palacci, DDS >> Head of the Brånemark Brånemark Osseointegration Centerinsight to hard and soft tissue management, cases performed by Dr. Palacci with comments Osseointegration Center 8-10 Rue Fargèsadvanced grafting techniques, the science and from Dr. Renouard, Prof. Nannmark and Dr. Marseille, France 13008 Marseilleevidence behind short and narrow implants in Richelme, at the BOC Marseille. Francevarious cases (from simple tooth to full arch >> Speaker to scientific Social dinner on Thursday evening.rehabilitation). meetings all around the Date Saturday: lectures and hands-on at Frank world and author ofTRAINING CENTER DESCRIPTION 21st-23rd of June 2012 Renouard’s vineyard in Vauvert: Scamandre. numerous scientific articlesThe Brånemark Osseointegration Center (BOC) Duration At the end of the course all the participants willwas founded in Gothenburg in 1989. Since From Thursday to Saturday be involved in a wine tasting session.then its mission is to provide treatment for Dr. Franck Renouard, DDS Participantspatients with severe oral, maxillo-facial >> Private practitioner inimpediments. Paris, France Minimum 10, maximum 25 >> European Association Cost for Osseointegration executive € 3000 (price includes local taxes) board since 2000 Registration >> Visiting Professor at the Liège Medicine Faculty, Belgium Send an email to edu@tecnoss-dental.com to receive an Enrolment Form. Dr. Ulf Nannmark, DDS, PhD >> Associate Professor at The Enrolment Form will have to be filled, the Göteborg University, signed and returned to Tecnoss Dental Sweden together with a down payment of 500 € to the BOC. >> Author of more than 100 scientific articles and book chapters PLEASE DO NOT BOOK FLIGHTS OR HOTELS >> Speaker at scientific UNTIL THE COURSE IS CONFIRMED meetings all around the world REGISTRATION DEADLINE Dr. Christian Richelme, DDS 1st May 2012 >> Private practitioner in Marseille, France Course language English >> A talented prosthodontist focused on implant therapy, Nearest airport occlusion and aesthetics Marseille (MRS) >> Working in tight collaboration with Dr. Palacci for many years 95
  • 40. An evidence-based educational path in maxillary sinus augmentation: EDUCATION LIVE SURGERY COURSEthe lateral approachABSTRACT PROGRAM LECTURERS Dr. Tiziano Testori, MD, DDS, FICD LocationThere are many patients with atrophic posterior Day 1- 13,00/19,00 >> Assistant Clinicalmaxillas requesting fixed prostheses. When the Theoretical session Professor and Head of the Lake Como Instituteresidual bone height is below 4 mm sinus lift Section of Implant Dentistry Via Rubini 22 - 22010 Como, Italy - Anatomy of the maxillary sinusprocedures remain the most viable therapeutic and Oral Rehabilitation, info@lakecomoinstitute.com - Basics about graft materials and membranes www.lakecomoinstitute.comoptions. This two-day course will present sinus School of Dentistry, I.R.C.C.S.elevation techniques and possible alternatives - Pre-surgical diagnosis, indications and Galeazzi Institute, University contraindications of Milan, Italy Dateto sinus elevation therapy from pre-surgicalplanning to prosthetic restoration. The scientific - Lateral window technique with videos >> Member of the Friday Sept 7th, 2012 | h 13,00-19,00program will be supported by multiple video - Evidence-based approach Editorial Board of: The Saturday Sept 8th, 2012 | h 08,30-18,30presentations, one interactive session, live International Journal of Oral and Maxillofacial - Sinus lift procedures: the scientific evidence Hospitalitysurgery and hands-on workshop on sinus Implants (IJOMI) and European Journal of Oralmodels. Day 2 - 8,30/18,30 Implantology (EJOI) Friday dinner and Saturday lunch included Interactive session with up to 4 cases presented >> Editor with R.L. Weinstein and S. Wallace ofTRAINING CENTER Participants by the participants the book “Maxillary Sinus Surgery andThe Lake Como Institute boasts internationally Live surgery Alternative Therapies” published by Maximum 25 participantsrecognized professionals in the field of Implant Quintessence Publishing 2009 - Treatment of complications CostDentistry and experts in all the other disciplines >> Author of 72 scientific publications in peer Workshop Early registration fee:of modern dentistry. The Institute mission is to reviewed journalsdeliver meticulous diagnosis, treatment and - Hands-on models for conventional lateral before March 31, 2012 = € 1.300+VAT window technique Dr. Marco Esposito, DDS, PhDcomprehensive management of complex cases. Regular fee: >> Associate Professor inA team of highly dedicated professionals work in - Hands-on models for piezoelectric technique after March 31, 2012 = € 1.500+VAT Biomaterials with theclose collaboration to achieve the best possible - Discussion Sahlgrenska Academy atoutcome for the patient. Registration Göteborg University, Sweden >> Editor in Chief of the Lake Como Institute European Journal of Oral Ms. Dayana Ciccolallo Implantology (EJOI) and Via Rubini 22 - Como, Italy Associate Editor of the Ph +39(0)31- 2759092 Cochrane Oral Health Group info@lakecomoinstitute.com >> author of more than 180 scientific publications www.lakecomoinstitute.com in international peer-reviewed journals Course language English Dr. Matteo Invernizzi, DDS >> DDS degree from Nearest airport University of Ferrara (Italy) Milano Malpensa (MPX) >> Senior lecturer at Lake Como Institute® Advanced Implant Training Center96
  • 41. Vertical and horizontal bone augmentation with xenogenic blocks EDUCATION LIVE SURGERY COURSEABSTRACT PROGRAM LECTURERS Dr. Marco Esposito, DDS, PhD LocationSp-Block and Dual-Block have been identified Friday night: arrival and welcome dinner. >> Associate Professor in Venice Dental Centeras extremely osteoconductive products with very Saturday’s Lectures and Live Surgeries will Biomaterials with theinteresting handling, providing a high rate of VIA G. Saragat 1/10 focus on the following topics: Sahlgrenska Academy atnew bone formation with good predictability in Göteborg University, Sweden 30174 Mestre (VE), Italyspecific clinical applications. - Scientific Evidence of bone augmentation Date >> Editor in Chief of the procedures European Journal of Oral Implantology (EJOI) and Saturday July 7th, 2012 - The inlay technique for posterior mandibleTRAINING CENTER Associate Editor of the Hospitality . Live Surgery 1: vertical augmentation Cochrane Oral Health GroupVenice Dental Center is a modern and elegant Friday dinner and Saturday lunch includeddental clinic conveniently located on Venice - The onlay technique for anterior maxilla >> author of more than 180 scientific publications in international peer-reviewed journals Participantsdoorstep. - Live Surgery 2: horizontal augmentation Dr. Pietro Felice, MD, DDS, PhD Minimum 15, maximum 30 >> Department of Cost Odontostomatological Sciences, University of € 500 + VAT Bologna, Italy Registration Please send an email to edu@tecnoss-dental.com to receive an Enrolment Form. The Enrolment Form will have to be filled, signed and returned to Tecnoss Dental Dr. Giuseppe Verdino, MD, DDS >> Ph.D in Maxillofacial together with a down payment of 200€ (fully Surgery Department, La refundable if course is cancelled). Sapienza University, Rome, PLEASE DO NOT BOOK FLIGHTS OR HOTELS Italy. UNTIL THE COURSE IS CONFIRMED >> Departement of Surgery, REGISTRATION DEADLINE Omegna Hospital, Italy. 1st April 2012 Course language English Nearest airport Venice (VCE) 97
  • 42. Source: Tecnoss Dental Media Library
  • 43. CERTIFICATIONSAND LITERATURE CE CERTIFICATES LABORATORY TESTS Source: Courtesy of Dr Ulf Nannmark, Göteborg University, Sweden ISO 13485 LITERATURE REVIEW SCIENTIFIC LITERATURE 99
  • 44. From nature to man“You may not immediatelynotice the xenogenic originof the Tecnoss®biomaterials, and thecollagen content preservedin each granule by theTecnoss® innovativebiotechnology.You may also not beaware of the excellentbiocompatibility and totalsafety guaranteed by theTecnoss® certifiedmanufacturing process.Not until the very momentin which you will use anTecnoss® grafting materialin your first surgery: aunique handling sensationand clinical response fromyour patient”Davide Oliva MD Tecnoss® develops and produces biomaterials Tecnoss® obtains its products from raw OsteoBiol® biomaterials are manufactured inManaging Director of animal origin to obtain Medical Devices of materials that derive from animals whose conformity with 93/42/EEC (D.Lgs 47/97 andTecnoss s.r.l. new conception, providing a valid and tissues have been evaluated as suitable fou next modifications), European rule. Italian innovating aid to the surgeon and a clinical human intake and come from suppliers Istituto Superiore di Sanità (ISS) is the Notified benefit to the patient. controlled by SSV. Body (0373) for CE mark of Tecnoss® Medical Devices. Materials are manufactured with an The biological matrix from which the innovative technology that conditions animal OsteoBiol® Medical Devices product line is All OsteoBiol® Products are sterile and for tissues in order to neutralize the antigenic derived has been subjected to ISO 10993 single use. Sterilization is performed with components present in animal bony tissues certification, that is a series of biological and gamma rays and is periodically checked; (achievement of biocompatibility) and allows histocompatibility tests carried out on both expiration date is 60 months from date of development of products unique in their kind, animal and human tissues showing the sterilization. capable of satisfying every surgical need. perfect and complete bioavailability and biocompatibility of the products. OsteoBiol® biomaterials provide excellent healing results thanks to an active Clinical studies with histological reports colonization of the receiving site by patient’s published on international scientific journals cells and therefore favor the process of confirm results achieved and therefore the restitutio ad integrum of injured tissues. quality of the production. 100
  • 45. certification CERTIFICATIONS CE CERTIFICATESAnnex III | Porcine and Equine Bone Matrix Annex III | Porcine and Equine Membranes Annex III | Equine FeltsSource: Tecnoss s.r.l. Source: Tecnoss s.r.l. Source: Tecnoss s.r.l.Annex V | Porcine and Equine Bone Matrix Annex V | Porcine and Equine Membranes Annex V | Equine FeltsSource: Tecnoss s.r.l. Source: Tecnoss s.r.l. Source: Tecnoss s.r.l. 101
  • 46. Biocompatibility tests | Gen-OsIn order to analyze the DIRECT CONTACT CYTOTOXICITY INTRACUTANEOUS REACTIVITY SYSTEMIC TOXICITYbiocompatibility of OsteoBiol® AIM: cytotoxic potential evaluation of OsteoBiol® Gen-Os AIM: local toxic effects evaluation of OsteoBiol® Gen-Os AIM: toxic systemic effects evaluation of OsteoBiol®grafting material, a battery of in grafting material grafting material Gen-Os grafting materialvitro and animal tests was MATERIALS AND METHODS MATERIALS AND METHODS MATERIALS AND METHODSperformed at Biolab S.p.A The direct contact cytotoxicity test was performed on a culture at A intracutaneous reactivity assay on rabbit was performed. 2 2 eluates of study material were prepared using as extractionlaboratory (Vimodrone, Milano, confluence of murine fibroblasts belonging to NCTC L929 clone eluates of study material were prepared using as extraction liquids liquids vegetable oil or saline. The extracts were obtained underItaly), in conformity with Good (Lgc Promochem, Teddington, Middlesex, UK) in exponential vegetable oil or saline. The extracts were obtained under static static conditions by dipping the study material in saline orLaboratory Practice (GLP – growth phase. An eluate with culture Medium was prepared, by conditions by dipping the study material in saline or vegetable oil vegetable oil to reach a 0.2g/ml weight/volume ratio. Each assay dipping the study material in culture Medium to obtain a 0,2g/ml to reach a 0.2g/ml weight/volume ratio. Each assay sample was sample was incubated for 72 hours at 37°C ±1°C temperature.certification number 158/245/05; weight/volume ratio. The assay sample was incubated for 72 incubated for 72 hours at 37°C ±1°C temperature. 0.2ml of each 50mg/Kg of saline extract was subcutaneously injected in a groupMinistry of Health Decree 10th hours at 37°C ±1°C temperature. Then, 2ml extract was extract was subcutaneously injected in 3 rabbits to evaluate of 5 mice and 50mg/Kg of vegetable oil extract wasMarch 2005). incubated with cultured NCTC L929 cells for a period of 48 hours macroscopic signs of cutaneous irritation such as erythema, intra-peritoneally administered to a group of 5 mice. All noticed in incubator at 37°C ±1°C temperature, with CO2 atmosphere in oedema and eschars. symptoms in treated animals during the following 72 hours of air. RESULTS observation were surveyed and registered. RESULTS During all observation period, no signs of erythema, oedema and RESULTS After 24 hours of incubation, no cytotoxic reaction is detectable in eschars were detected in treated rabbits. None of mice treated with saline or vegetable oil extracts from cultured treated cells; in fact there is no presence of both cells CONCLUSIONS study material showed toxic symptoms. lacking intra-cytoplasmatic granulations and areas characterized OsteoBiol® Gen-Os study material satisfies the assay conditions, CONCLUSIONS by wide cellular lysis (reactivity grade: 0.00). in fact all LOCAL TOXIC EFFECTS were ABSENT, as stated in UNI On the base of results obtained, interpreted as stated in UNI EN CONCLUSIONS EN ISO 10993-10:2004 rule. ISO 10993-11:1997 rule, OsteoBiol® Gen-Os grafting material As stated in UNI EN ISO 10993: 5, 2000 rule, OsteoBiol® can be considered as NON TOXIC. Gen-Os study material must be considered as NON CYTOTOXIC. DELAYED HYPERSENSITIVITY SALMONELLA TYPHIMURIUM REVERSION AIM: sensitizing effects analysis of OsteoBiol® Gen-Os grafting material AIM: mutagenesis effects analysis of OsteoBiol® Gen-Os MATERIALS AND METHODS grafting material 2 eluates of study material were prepared using as extraction liquids vegetable oil or saline. The extracts were obtained under static MATERIALS AND METHODS conditions by dipping the study material in saline or vegetable oil to reach a 0.2g/ml weight/volume ratio. Each assay sample was Salmonella typhimurium assay (reversion of mutation) was incubated for 72 hours at 37°C ±1°C temperature. 15 guinea-pigs were used for each eluate analysis, whom 10 were treated with each performed on 5 mutant strains of Salmonella typhimurium study material extract and 5 as controls. Cutaneous sensitization assay is characterized by an induction phase and by a challenge phase. (TA1535, TA1537, TA98, TA100, TA102). The mutagenic activity Induction phase | During induction phase the group of 10 treated guinea-pigs was inoculated with 3 couples (0,1ml each) of intradermal of study material was defined by the computation of revertant injections as follows: colonies of test cultures in comparison with the number of revertant colonies of control cultures. This activity was evaluated 1°: Complete Freund Adjuvant (FCA) in deionized water (1:1 ratio) both in presence or absence of an enzymatic system of metabolic 2°: study material eluate activation with the method of direct incorporation into plate. For the assay, 2 eluates of study material were prepared using saline 3°: study material eluate + FCA (1:1 ratio). or DMSO as extraction liquids. The extracts were obtained under 5 control guinea-pigs received the same injection couples as treated group, but in the 2nd injection only extraction liquid was inoculated static conditions by dipping the study material in saline or DMSO (vegetable oil and saline) and in the 3rd injection extraction liquid + FCA (1:1 ratio). After 6 days from intradermal injection in both treated to reach a 0.2g/ml weight/volume ratio. Each assay sample was and control animals, a topical application through massage of 0.5ml Sodium Lauryl Sulfate at 10%. After 7 days from intradermal incubated for 72 hours at 37°C ±1°C temperature. injection, on the skin of 10 treated animals the study material extract was applied in a volume of 0.5ml/animal for a incubation period of RESULTS 48 hours. The same treatment was performed in the control group, using the respective extraction liquid. The analysis performed on test strains (incubation with study Challenge phase | After 21 days from the beginning of treatment, on all treated and control animals the challenge phase was induced, by material eluates) about genetic characteristics demonstrated the applying on the right side of their back 0.5ml of study material extract and on their left side the respective extraction liquid (vegetable oil maintenance of required genetic characters. Moreover, the study or saline). The bandages were left in site for 24 hours. After 24 and 48 hours from bandages removal all reactions of both treated and material extracts were both non toxic nor harmful on bacteria control animals were evaluated. used for assays. RESULTS CONCLUSIONS No reactions of erythema and/or oedema were detectable in both treated and control animals. As stated in ISO 10993-11:1993 rule, OsteoBiol® Gen-Os study CONCLUSIONS material was NON MUTAGENIC, both in presence or absence of On the base of results obtained, interpreted as stated in UNI EN ISO 10993-10:2002 rule, OsteoBiol® Gen-Os study material must be metabolic activation. defined as NON SENSITIZING. 102
  • 47. Biocompatibility tests | Evolution CERTIFICATIONS LABORATORY TESTSDIRECT CONTACT CYTOTOXICITY INTRACUTANEOUS REACTIVITY TEST SYSTEMIC TOXICITY TESTAIM: cytotoxic potential evaluation of OsteoBiol® AIM: local toxic effects evaluation of OsteoBiol® AIM: systemic toxicity effects evaluation ofEvolution resorbable membrane Evolution resorbable membrane OsteoBiol® Evolution resorbable membraneMATERIALS AND METHODS MATERIALS AND METHODS MATERIALS AND METHODSThe direct contact cytotoxicity test was performed on a culture A intracutaneous reactivity assay on rabbit was performed. 2 2 eluates of study material were prepared using as extractionat confluence of murine fibroblasts belonging to NCTC L929 eluates of study material were prepared using as extraction liquids vegetable oil or saline. The extracts were obtainedclone (Lgc Promochem) in exponential growth phase. The liquids vegetable oil or saline. The extracts were obtained under static conditions by dipping the study material in salinestudy material was incubated with cultured NCTC L929 cells under static conditions by dipping the study material in saline or vegetable oil to reach a 6cm2/ml surface/volume ratio.in monolayer for a period of 24 hours in incubator at 37°C or vegetable oil to reach a 6cm2/ml surface/volume ratio. Each assay sample was incubated for 72 hours at 37°C ±1°C±1°C temperature, with CO2 atmosphere in air. After 24 Each assay sample was incubated for 72 hours at 37°C ±1°C temperature. 50mg/Kg of saline extract was subcutaneouslyhours incubation, the cell culture was observed to evaluate temperature. 0.2ml of each extract were subcutaneously injected in a group of 5 mice and 50mg/Kg of vegetable oilbiological reactivity. injected in 3 rabbits to evaluate macroscopic signs of extract was intra-peritoneally administered to a group of 5RESULTS cutaneous irritation such as erythema, oedema and eschars. mice. All noticed symptoms in treated animals during theAfter 24 hours of direct contact in cultured treated cells, no RESULTS following 72 hours of observation were surveyed andareas, under or surrounding the material, was deformed During all observation period, no signs of erythema, oedema registered.and/or degenerated (reactivity grade: 0.00). and eschars were detected in treated rabbits. RESULTSCONCLUSIONS CONCLUSIONS None of mice treated with saline or vegetable oil extractsAs stated in UNI EN ISO 10993: 5, 2000 rule, OsteoBiol® OsteoBiol® Evolution resorbable membrane satisfies the from study membrane showed toxic symptoms.Evolution resorbable membrane must be considered as assay conditions, in fact all LOCAL TOXIC EFFECTS were CONCLUSIONSNON CYTOTOXIC. ABSENT, as stated in UNI EN ISO 10993-10:2004 rule. On the base of results obtained, interpreted as stated in UNI EN ISO 10993-11:1997 rule, OsteoBiol® Evolution resorbable membrane can be considered as NON TOXIC.DELAYED HYPERSENSITIVITY SALMONELLA TYPHIMURIUM REVERSIONAIM: sensitizing effects analysis of OsteoBiol® Evolution resorbable membrane AIM: mutagenesis effects analysis of OsteoBiol®MATERIALS AND METHODS Evolution resorbable membrane2 eluates of study material were prepared using as extraction liquids vegetable oil or saline. The extracts were obtained under MATERIALS AND METHODSstatic conditions by dipping the study material in saline or vegetable oil to reach a 6cm2/ml surface/volume ratio. Each assay Salmonella typhimurium assay (reversion of mutation) wassample was incubated for 72 hours at 37°C ±1°C temperature. 15 guinea-pigs were used for each eluate analysis, whom 10 performed on 5 mutant strains of Salmonella typhimuriumwere treated with each study material extract and 5 as controls. Cutaneous sensitization assay is characterized by an induction (TA1535, TA1537, TA98, TA100, TA102). The mutagenicphase and by a challenge phase. activity of study material was defined by the computation ofInduction phase | During induction phase the group of 10 treated guinea-pigs was inoculated with 3 couples (0.1ml each) of revertant colonies of test cultures in comparison with theintradermal injections as follows: number of revertant colonies of control cultures. This activity was evaluated both in presence or absence of an enzymatic1°: Complete Freund Adjuvant (FCA) in deionized water (1:1 ratio) system of metabolic activation with the method of direct2°: study material eluate incorporation into plate. For the assay, 2 eluates of study material were prepared using saline or DMSO as extraction3°: study material eluate + FCA (1:1 ratio) Source: Courtesy of Dr Ulf Nannmark, Göteborg University, Sweden liquids. The extracts were obtained under static conditions by5 control guinea-pigs received the same injection couples as treated group, but in the 2nd injection only extraction liquid was dipping the study material in saline or DMSO to reach ainoculated (vegetable oil and saline) and in the 3rd injection extraction liquid + FCA (1:1 ratio). After 6 days from intradermal 6cm2/ml surface/volume ratio. Each assay sample wasinjection in both treated and control animals, a topical application through massage of 0.5ml Sodium Lauryl Sulfate at 10%. After incubated for 72 hours at 37°C ±1°C temperature.7 days from intradermal injection, on the skin of 10 treated animals the study material extract was applied in a volume of RESULTS0.5ml/animal for a incubation period of 48 hours. The same treatment was performed in the control group, using the respective The analysis performed on test strains (incubation with studyextraction liquid. material eluates) about genetic characteristics demonstratedChallenge phase | After 21 days from the beginning of treatment, on all treated and control animals the challenge phase was the maintenance of required genetic characters. Moreover,induced, by applying on the right side of their back 0.5ml of study material extract and on their left side the respective extraction the study material extracts were both non toxic nor harmfulliquid (vegetable oil or saline). The bandages were left in site for 24 hours. After 24 and 48 hours from bandages removal all on bacteria used for assays.reactions of both treated and control animals were evaluated. CONCLUSIONSRESULTS As stated in ISO 10993-11:1993 rule, OsteoBiol® EvolutionNo reactions of erythema and/or oedema were detectable in both treated and control animals. resorbable membrane was NON MUTAGENIC, both inCONCLUSIONS presence or absence of metabolic activation.On the base of results obtained, interpreted as stated in UNI EN ISO 10993-10:2002 rule, OsteoBiol® Evolution resorbablemembrane must be defined as NON SENSITIZING. 103
  • 48. Biocompatibility tests | mp3DIRECT CONTACT CYTOTOXICITY INTRACUTANEOUS REACTIVITY SYSTEMIC TOXICITYAIM: cytotoxic potential evaluation of OsteoBiol® mp3 AIM: local toxic effects evaluation of OsteoBiol® mp3 AIM: systemic toxic effects evaluation of OsteoBiol® mp3grafting material grafting material grafting materialMATERIALS AND METHODS MATERIALS AND METHODS MATERIALS AND METHODSThe cytotoxicity direct contact test was performed on a confluent An intracutaneous reactivity assay on albino rabbit was In the acute systemic toxicity test two extracts of test device wereNCTC L929 (Mammal fibroblasts ATCC CCL1 NCTC Clone L929) performed. Two extracts of test product were prepared using prepared using physiological solution and vegetable oil as liquidcell culture in exponential phase of growth. physiological solution and vegetable oil as liquid of extraction. of extraction. The extracts of the test product were performed byThe test product was applied to the monolayer of NCTC L929 and The extracts of the test product were performed by submerging the submerging the test sample into both solvents. Then the testwas incubated at 37°C ±1°C in CO2 atmosphere for 24 hours. test sample into both solvents. Then the test sample was incubated sample was incubated for 72 hours at temperature of 37°C ±1°CAfter 24 hours of incubation the cells cultures were observed to for 72 hours at temperature of 37°C ±1°C in dynamic conditions. in dynamic conditions. An extract of test device in physiologicalevaluate the biological reactivity (cell degeneration and Each extract were intracutaneously injected in albino rabbits. All solution was intravenous injected in a group of mice and othermalformations). animals have been observed at 24, 48 and 72 hours for injection extract in vegetable oil was intraperitoneally injected in otherRESULTS for evaluated each toxic symptom and macroscopical skin group of mice. All animals were observed immediately afterAfter 24hrs of contact, in the cells treated with test product no reactions, as erythema, oedema and eschar. injection and after 4, 24, 48 and 72 hours for evaluated eachdetectable malformed or degenerated zone around or under RESULTS symptom as tremors, convulsions, tachycardia, etc.specimen was observed (reactivity grade 0). During the study, all the treated sites showed no sign of erythema RESULTSCONCLUSIONS nor sign of oedema. All the control sites showed no sign of In none of the treated animals toxic signs or symptoms wereOn the basis of the results, interpreted according to EN ISO erythema nor sign of oedema. observed.10993-5:2009, the test product must be considered NOT CONCLUSIONS CONCLUSIONSCYTOTOXIC. On the basis of the results, interpreted according to EN ISO On the basis of the results, interpreted according to EN ISO 10993-10:2002, the test product SATISFIES the requirements of 10993-11:2006, the test product must be considered NON the test. TOXIC.DELAYED HYPERSENSITIVITY SALMONELLA TYPHIMURIUM REVERSE MUTATION IN BONE IMPLANTAIM: hypersensitivity effects evaluation of OsteoBiol® AIM: mutagenesis effects evaluation of OsteoBiol® mp3 AIM: osteogenesis activity evaluation of OsteoBiol® mp3mp3 grafting material grafting material grafting materialMATERIALS AND METHODS MATERIALS AND METHODS MATERIALS AND METHODSTwo extracts of the test product were prepared both in vegetable oil The test was performed on five mutant strains of Salmonella In bone implant test, the test samples were implanted in three sitesand in physiological solution in order to perform the tests for typhimurium (TA1535, TA1537, TA98, TA100, TA102). The of right femur of 4 white rabbits; USP Reference Standard Negativedelayed-type hypersensivity. The extracts of the test product were mutagenic activity of the test sample was determined by comparing Control Plastic were implanted in three sites of the controlateralperformed by submerging the test sample into both solvents. Then number of reverting colonies with the number of the reverting side. Animals were sacrificed after 4 and 12 weeks. At the end ofthe test sample was incubated for 72 hours at temperature of 37°C organisms in the control cultures. The extracts of the test product the study, histopathology of the implanted sites (for each animal 1±1°C in dynamic conditions. For each extract guinea pigs were were performed by submerging the test sample into physiological treated site and 1 control site) were performed.used. The test is characterized by an induction phase and challenge solution and DMSO. Then the sample was incubated for 72 hours RESULTSphase. In induction phase, the guinea pigs were treated with at temperature of 37°C ±1°C in dynamic conditions. After 4 weeks the bone holes treated with the test sample showedintradermal injections. 6 days after the beginning of treatment on RESULTS an active neo-osteogenesis. After 12 weeks the treated bone holesthe all animals, a topical application was performed. After 7 days No increase in the number of revertant colonies per plate in any were completely closed.from the intradermal injections, the extracts of test product were strain with or without metabolic activation system was detected.applied. The application lasted 48 hours. The same treatment wasperformed on control guinea pigs using only extraction liquid. The CONCLUSIONSchallenge phase, 21 days after the beginning of treatment, was On the basis of results, evaluated according to EN ISOperformed applying by an occlusive patch on all the animals about 10993-3:2003, the test product, undergone to Ames test, is1ml of the extract on the left side and about 1ml of the solvent on NON-MUTAGENIC either in the presence or absence ofthe right side. The patch was left on for 24 hours. 48 and 72 hours metabolic activation.after the beginning of this phase, the tested animals and the controlanimals were observed. No abnormalities were observed in theanimals used as treated and as control. On the basis of the results,interpreted according to EN ISO 10993-10:2002, the test productcan be considered NON SENSITIZING.RESULTSNo abnormalities were observed in the animals used as treatedand as control.CONCLUSIONSOn the basis of the results, interpreted according to EN ISO10993-10:2002, the test product can be considered NONSENSITIZING.104
  • 49. ISO TUV 13485 quality certificate CERTIFICATIONS ISO 13485 REGULATIONS ON MANUFACTURING PROCESS UNI EN ISO 13485:2004 Medical devices – Quality management systems – Requirements for regulatory purposes Directive 93/42/CEE and relative amendments UNI CEI EN ISO 14971:2009 “Application of risk management to medical devices” UNI EN ISO 10993-1:2004 “Biological evaluation to medical devices. Part 1: Evaluation and testing” UNI EN 12442:2002[1-2] “Animal tissues and their derivatives utilized in the manufacture of medical devices” UNI EN ISO 11137-1:2006 “Sterilization of health care products - Radiation - Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices” UNI EN ISO 11137-1:2008 “Sterilization of health care products - Radiation - Part 2: Establishing the sterilization dose” EN 556-1:2002 and EN 556-1:2001/AC:2006 “Sterilization of medical devices. Requirements for medical devices to be designated “STERILE”. Requirements for terminally sterilized medical devices“ UNI CEI EN 980:2009 “Graphical symbols for use in the labelling of medical devices” MEDDEV 2.12-1 rev 6 Guidelines on a medical devices vigilance - 2009 105
  • 50. Clinical summary of literature on OsteoBiol® biomaterials Xenografts are the most widely used and An experimental study by Nannmark and Sennerby Cardaropoli D. and G. (JPRD, 2008) grafted CCPB scientifically documented biomaterials for bone (CIDRR, 2008) investigated in vivo the bone tissue in posterior teeth post-extractive sockets: 85% of regeneration in dentistry. The OsteoBiol® xenograft response to dry CCPB vs. pre-hydrated CCPB the initial crestal width has been preserved using line (Tecnoss®, Coazze, Italy) includes different mixed with collagen gel. The histological analysis this procedure, while with spontaneous healing a types of collagenated bone substitutes and showed no significant difference between the two 50% reduction of buccolingual width after 12 membranes, of porcine and equine origin. bone substitutes, with new bone formation directly months has been reported in a previous study on the particles. The new bone area increased (JPRD, 2003, 23: 313-323). The results of the A study by Figuejredo et al. (JBMR 2009) progressively both in test and control sites, while investigation promote the use of a porcine bone investigated the physiochemical characterization of the residual biomaterial area decreased substitute to fill the postextraction site of posterior several biomaterials used in dentistry, comparingAntonio Barone progressively due to osteoclastic resorption. The teeth to avoid alveolar bone loss. them with human bone. An OsteoBiol®DDS, PhD, MSc collagen membrane used to protect both grafts collagenated cortico-cancellous porcine bone A second clinical study by Barone et al. (JP 2008) , fulfilled its function and was well integrated with theEuropean Master Oral Medicine particulate material (CCPB) was included in this compares the use of pre-hydrated CCPB with overlaying soft tissues. The study demonstrated thatand Surgery comparative analysis, using the following spontaneous socket healing to verify if the porcine bone exhibits good biocompatibility and parameters: particle size, porosity, real density, biomaterial grafted contributes to reduceAssistant Professor University of osteoconductive properties and is resorbed byGenova, Italy specific surface area, infrared spectroscopy, X-ray horizontal and vertical ridge reduction. The grafted surface osteoclasts. diffraction. In particular, the real density of CCPB is material reduced significantly both vertical andClinical Assistant Professor extremely similar to natural human bone, due to Another experimental study was conducted by horizontal bone loss, while histomorphometricDepartment of Oral and the collagen content. Infrared spectra of Calvo et al. (CIDRR, 2011), who verified the analysis showed a higher amount of trabecularMaxillofacial Surgery, State OsteoBiol® particles and natural human bone are biocompatibility of the material and its resorption 4 bone in grafted sites compared to extraction aloneUniversity of New York at Buffalo,USA also very similar, although they have different months after the placement in rabbits’ tibiae: the control sites. origins, whereas calcinated human bone, grafted material acted as a scaffold for bone cells,Visiting Assistant Professor hydroxyapatite and anorganic bovine bone have leading to progressive increases in bone regrowth Crespi et al. (JOMI, 2011) confirmed theDepartment of Periodontology, different FTIR spectra. Similar observations can be in and around the xenograft. biocompatibility and high osteoconductivity ofState University of New York at made analyzing the XRD spectra, that demonstrate Osteointegration of the grafts was investigated by CCPB in a split mouth study for alveolarStony Brook, USA regeneration by means of histomorphometries and once more the similarity between natural human Scarano et al. (CIDRR, 2011) who analyzedPresident Italian Society of Oral bone and CCPB: these patterns represent the histologically and histomorphometrically samples osteoblast-specific gene expression.Surgery and Implantology dual-phase composition of both natural human of bone taken from sinuses grafted with CCPB after Several clinical studies investigated the effects ofMember Executive Committee bone and OsteoBiol®, consisting in hydroxiapatite 4 and 6 months: with these analyses it was possible porcine bone in maxillary sinus floor elevation.European Federation of Oral (sharp peaks) and collagen (broad band). These to confirm that grafted biomaterial particles were The first study by Barone at al. (JOMI, 2005)Surgery Societies differences, in chemical nature and phase surrounded by newly formed bone, with no signs of reports a histologic and histomorphometric composition, between anorganic and collagenated inflammatory reactions and no gaps at the comparison at 5 months of maxillary bone biomaterials are expected to affect the bone-biomaterial interface. regenerated via lateral approach with 100% performance of these materials after in vivo autogenous bone (control) vs. a mixture of 50% A comparison between different materials was implantation. autogenous bone and 50% CCPB (test). No made by Ramírez-Fernandez et al. (COIR, 2011) The biocompatibility of porcine bone substitutes who implanted of xenografts of bovine and porcine significant differences in new bone percentages has been tested in vitro by Trubiani et al. (JIP 2007) origin in rabbits. After 4 months measurements were observed in biopsies from control and test using PDL-MSC’s: cellular colonization and revealed that both materials are osteoconductive sites: CCPB particles were well integrated and in proliferation was evident on porcine bone and do not interfere with normal reparative bone complete continuity with the new bone tissue granules, with no signs of infection in culture cell processes, while collagenized porcine granules formations. No evidence of inflammatory infiltrate, medium. PDL-MSCs cells were able to differenciate were more resorbable than bovine grafts with necrosis, or foreign body reaction was observed in in osteoblasts in vitro and after 30 days of similar granulometry. any of the test biopsies. CCPB was not completely induction, cells were separated from substrate and resorbed at 5 months, but the particles were wellOspedale Versilia Clinical studies investigated the efficacy of porcine integrated and in complete continuity with the newdivisione di odontoiatria able to organize themselves as a single nodule biomaterials on alveolar ridge preservation after bone tissue formations.Lido di Camaiore (LU), Italy englobing all porcine bone particles. tooth extraction.barosurg@gmail.com 106
  • 51. LITERATURE LITERATURE REVIEW 2012 Orsini at al. (JOP 2006) performed a , The results showed that implants placed in Horizontal regeneration (ridge splitting histomorphometric analysis at 5 months of augmented sinuses exhibit a successful tissue technique) with CCPB paste has been described maxillary bone regenerated with 100% porcine integration with high survival rate over 6 years in a case report by Calvo Guirado et al. (JIDA, cortical bone. Light microscopy (LM) and of follow-up. 2007) with the objective to verify at 4 months if transmission electron microscopy (TEM) the biomaterial grafted contributes to Regeneration of dehiscences with porcine observations were also made. LM showed that regenerate bone around implants, allowing a most particles were surrounded by newly derived biomaterials has been investigated in ridge width gain. Second stage surgery formed bone, with no evidence of acute two studies: in the first study Covani et al. (JP, revealed the implants to be covered with inflammatory infiltrate. Newly formed bone 2006) evaluated the clinical success at 12 regenerated bone of D5 density on the Misch area was 38% ± 2.8% while residual graft area months of implants placed immediately after classification system, while alveolar ridge was 31% ± 1.6%. New bone in contact with explantation of failed implants, regenerating all experienced a net gain of 3mm. Within the cortical porcine bone particles presented all dehiscences or peri implant bone defects larger limitations of a single case report, the authors phases of bone formation, and showed than 2 mm with CCPB and collagen concluded that collagenized pig bone paste features similar to the pre-existing osseous membranes. Cortico-cancellous porcine maintained separation between the two cortical tissue, thus indicating the biocompatible particles were used to prevent the collapse of plates and led to new bone formation between properties of this graft. the membrane and maintain space beneath the implants after four months. the membrane for bone regeneration: no Barone et al. (COIR, 2008) reports the use of residual bone defects were observed after Scarano et al. (COIR, 2011) presented a case 100% pre-hydrated CCPB in lateral access implants sites were probed at second stage series of vertical ridge augmentations with sinus lift (26 sinuses) using a collagen surgery, and all implants were asymptomatic equine collagenated cancellous blocks used membrane to cover the bony window. All and not mobile. with the inlay technique: after 4 months, newly patients had uneventful healing and no signs or formed bone was present near the symptoms of maxillary sinus disease were The second study by the same authors (JOMI, osteotomized segments, in close contacts with observed after the augmentation surgical 2008) evaluated buccal bone regeneration the biomaterial. Moreover, histomorphometrical procedures. around implants placed immediately after results (44±2,1 % newly formed bone, 18±0,8 extraction with flap elevation (control group) In JPRD (2008), (Barone et al., JPRD 2008) % marrow spaces, 33±2,4 % residual and without flap (test group). All dehiscences investigated the effect of CCBP gel in crestal biomaterial) suggested that the blocks can be were grafted with CCPB gel and collagen access sinus lift procedures and dehiscence considered as a good alternative to membranes and clinical success was assessed regeneration. The biomaterial was introduced autogenous bone using the so-called at 6 months using three parameters: DIB into receptor site after sinus floor fracture with “sandwich technique” in atrophic posterior (distance between implant shoulder and first last osteotome, and pressed into fractured sinus mandibles. bone-implant contact) – ISQ (implant stability floor area. One of 12 implants failed during quotient) and DIC (distance between implant the first 6 weeks, due to abscess; all remaining shoulder and crestal bone at the midbuccal In conclusion, the OsteoBiol® implants were successful at 6 months and aspect). All grafting procedures were collagenated porcine bone substitutes showed no signs of mobility, pain, suppuration successfully carried out as planned without any and collagen membranes have shown or absence of peri-implant radiolucency. No complications, and postsurgical healing phase positive clinical and biological results in implants failed after definitive prosthetic was uneventful for all patients. No peri-implant all the scientific articles reviewed in this rehabilitation, while bone augmentaton into bone defect was observed at second stage summary. sinus floor was 4.2 mm ±1.4 mm and surgery after 6 months, while the neck of 1 of remained stable after 18 months. These biomaterials can therefore be the implants from the flapless group was considered as predictable and effective In a comparative cohort study, Barone et al. (JP, covered with regenerated bone. Slotte et al. medical devices for the regeneration of 2011) evaluated the survival rate of implants (CIDRR, 2011) placed CCPB into peri-implant bone defects in dentistry. placed in native bone and in sinuses bone lesions and observed the results after 12 augmented via lateral approach, according to months of healing, when the favorable a 2-stage technique with a mixture 1:1 of bone properties of the particles in enhancing Antonio Barone graft and autogenous bone. regeneration in that type of defect was evident. DDS, PhD, MScHistology of OsteoBiol® bone matrixSource: Courtesy of Dr Ulf Nannmark, University of Göteborg, Sweden 107
  • 52. Scientific literature“Tecnoss® Dental is 9 | ORSINI G, SCARANO A, PIATTELLI M, PICCIRILLI M, CAPUTI S, PIATTELLI Aconstantly investing a HISTOLOGIC AND ULTRASTRUCTURAL ANALYSIS OFconsiderable budget in REGENERATED BONE IN MAXILLARY SINUS AUGMENTATION USING A PORCINE BONE-DERIVEDclinical and experimental BIOMATERIALstudies in order to JOURNAL OF PERIODONTOLOGY, 2006 DEC;77(12):1984-90continuously improve the 10 | TRUBIANI O, SCARANO A, ORSINI G, DI IORIO D, DARCANGELO C, PICCIRILLI M, SIGISMONDO M, CAPUTI Sscientific knowledge on THE PERFORMANCE OF HUMAN PERIODONTALOsteoBiol® products” LIGAMENT MESENCHYMAL STEM CELLS ON XENOGENIC BIOMATERIALSMarco Boarolo BEc INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2007 JAN-MAR; 20(1 SUPPL 1):87-91Managing Director andScientific Coordinator 11 | BARONE A, COVANI U MAXILLARY ALVEOLAR RIDGE RECONSTRUCTION WITHTecnoss® Dental s.r.l. NON- VASCULARIZED AUTOGENOUS BLOCK BONE: CLINICAL RESULTS JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2007 OCT;65(10):2039-46 12 | CALVO GUIRADO JL, PARDO ZAMORA G, SAEZ YUGUERO MR RIDGE SPLITTING TECHNIQUE IN ATROPHIC ANTERIOR MAXILLA WITH IMMEDIATE IMPLANTS, BONE REGENERATION AND IMMEDIATE TEMPORISATION: A CASE REPORT JOURNAL OF IRISH DENTAL ASSOCIATION, 2007 WINTER;53(4):187-90 13 | DEL CORSO M SOFT TISSUE RESPONSE TO PLATELET RICH FIBRIN: CLINICAL EVIDENCES COSMETIC DENTISTRY, 2008, 3: 16-20 14 | BARONE A, SANTINI S, MARCONCINI S, GIACOMELLI L,GHERLONE E, Histology at 3 months. Human mandible grafted with OsteoBiol® Sp-Block Source: Courtesy of Dr P Felice, Bologna, Italy. Histology by Prof U Nannmark, University of Göteborg, Sweden COVANI U OSTEOTOMY AND MEMBRANE ELEVATION DURING THE MAXILLARY SINUS AUGMENTATION PROCEDURE. A 1 | COVANI U, AMERI S, CRESPI R, BARONE A 5 | RINNA C, UNGARI C, SALTAREL A, CASSONI A, REALE G COMPARATIVE STUDY: PIEZOELECTRIC DEVICE VS. PRESERVAZIONE DEL PROCESSO ALVEOLARE CON OSSO ORBITAL FLOOR RESTORATION CONVENTIONAL ROTATIVE INSTRUMENTS ETEROLOGO. CONSIDERAZIONI ISTOLOGICHE JOURNAL OF CRANIOFACIAL SURGERY, 2005 NOV; CLINICAL ORAL IMPLANTS RESEARCH, 2008 MAY;19(5):511-5. ITALIAN ORAL SURGERY, 2004, VOL 3, 1: 17-23 16(6):968-72 EPUB 2008 MAR 26 2 | CASSETTA M, CALASSO S, VOZZA I, DELLAQUILA D 6 | BARONE A, AMERI S, COVANI U 15 | BARONE A, CORNELINI R, CIAGLIA R, COVANI U REHABILITATION OF ATROPHIC ALVEOLAR CRESTS WITH IMMEDIATE POSTEXTRACTION IMPLANTS: TREATMENT IMPLANT PLACEMENT IN FRESH EXTRACTION SOCKETS CYLINDRICAL SANDBLASTED AND ACID ETCHED OF RESIDUAL PERI-IMPLANT DEFECTS. A RETROSPECTIVE AND SIMULTANEOUS OSTEOTOME SINUS FLOOR IMPLANTS: A PILOT STUDY ANALYSIS ELEVATION: A CASE SERIES EUROPEAN JOURNAL OF IMPLANT PROSTHODONTICS, EUROPEAN JOURNAL OF IMPLANT PROSTHODONTICS, INTERNATIONAL JOURNAL OF PERIODONTICS AND 2005;(3)1:133-144 2006,2: 99-106 RESTORATIVE DENTISTRY, 2008 JUN; 28(3):283-9 3 | ARCURI C, CECCHETTI F, GERMANO F, MOTTA A, 7 | BARONE A, SANTINI S, SBORDONE L, CRESPI R, COVANI U 16 | BARONE A, ALDINI NN, FINI M, GIARDINO R, CALVO SANTACROCE C A CLINICAL STUDY OF THE OUTCOMES AND GUIRADO JL, COVANI U CLINICAL AND HISTOLOGICAL STUDY OF A XENOGENIC COMPLICATIONS ASSOCIATED WITH MAXILLARY SINUS XENOGRAFT VERSUS EXTRACTION ALONE FOR RIDGE BONE SUBSTITUTE USED AS A FILLER IN POSTEXTRACTIVE AUGMENTATION PRESERVATION AFTER TOOTH REMOVAL: A CLINICAL ALVEOLUS INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL AND HISTOMORPHOMETRIC STUDY MINERVA STOMATOLOGICA, 2005 JUN;54(6):351-62 IMPLANTS, 2006 JAN-FEB; 21(1):81-5 JOURNAL OF PERIODONTOLOGY, 2008 AUG;79(8):1370-7 4 | BARONE A, CRESPI R, ALDINI NN, FINI M, GIARDINO R, 8 | COVANI U, BARONE A, CORNELINI R, CRESPI R 17 | COVANI U, CORNELINI R, BARONE A COVANI U CLINICAL OUTCOME OF IMPLANTS PLACED BUCCAL BONE AUGMENTATION AROUND IMMEDIATE MAXILLARY SINUS AUGMENTATION: HISTOLOGIC AND IMMEDIATELY AFTER IMPLANT REMOVAL IMPLANTS WITH AND WITHOUT FLAP ELEVATION: A HISTOMORPHOMETRIC ANALYSIS JOURNAL OF PERIODONTOLOGY, 2006 APR;77(4):722-7 MODIFIED APPROACH INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL IMPLANTS, 2005 JUL-AUG; 20(4):519-25 IMPLANTS, 2008 SEP-OCT; 23(5):841-6 108
  • 53. LITERATURE INTERNATIONAL PUBLICATIONS18 | CARDAROPOLI D, CARDAROPOLI G 28 | CRESPI R, CAPPARÈ P GHERLONE E , 37 | SCARANO A, CARINCI F, ASSENZA B, PIATTELLI M, 45 | HINZE M, VRIELINCK L, THALMAIR T, WACHTEL H, BOLZ WPRESERVATION OF THE POSTEXTRACTION DENTAL IMPLANTS PLACED IN EXTRACTION SITES MURMURA G, PIATTELLI A ZYGOMATIC IMPLANT PLACEMENT IN CONJUCTIONALVEOLAR RIDGE: A CLINICAL AND HISTOLOGIC GRAFTED WITH DIFFERENT BONE SUBSTITUTES: VERTICAL RIDGE AUGMENTATION OF ATROPHIC WITH SINUS BONE GRAFTING: THE "EXTENDED SINUSSTUDY RADIOGRAPHIC EVALUATION AT 24 MONTHS POSTERIOR MANDIBLE USING AN INLAY ELEVATION TECHNIQUE". A CASE-COHORT STUDYINTERNATIONAL JOURNAL OF PERIODONTICS AND JOURNAL OF PERIODONTOLOGY, 2009 OCT; TECHNIQUE WITH A XENOGRAFT WITHOUT ORAL AND CRANIOFACIAL TISSUE ENGINEERING, 2011;RESTORATIVE DENTISTRY, 2008 OCT; 28(5):469-77 80(10):1616-1621 MINISCREWS AND MINIPLATES: CASE SERIES 1:188-19719 | NANNMARK U, SENNERBY L CLINICAL ORAL IMPLANTS RESEARCH, 2011 46 | IEZZI G, DEGIDI M, PIATTELLI A, MANGANO C, 29 | RINNA C, REALE G, FORESTA E, MUSTAZZA MCTHE BONE TISSUE RESPONSES TO PREHYDRATED OCT;22(10):1125-30 SCARANO A, SHIBLI JA, PERROTTI V MEDIAL ORBITAL WALL RECONSTRUCTION WITHAND COLLAGENATED CORTICO-CANCELLOUS SWINE BONE CORTEX 38 | PAGLIANI L, ANDERSSON P LANZA M, NAPPO A, , COMPARATIVE HISTOLOGICAL RESULTS OFPORCINE BONE GRAFTS: A STUDY IN RABBIT THE JOURNAL OF CRANIOFACIAL SURGERY, 2009; 20(3) VERROCCHI D, VOLPE S, SENNERBY L DIFFERENT BIOMATERIALS USED IN SINUSMAXILLARY DEFECTS A COLLAGENATED PORCINE BONE SUBSTITUTE FOR AUGMENTATION PROCEDURES: A HUMAN STUDY 30 | CARDAROPOLI D, CARDAROPOLI G AT 6 MONTHSCLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, AUGMENTATION AT NEOSS IMPLANT SITES: A HEALING OF GINGIVAL RECESSIONS USING A CLINICAL ORAL IMPLANTS RESEARCH, 2011 NOV 2, EPUB2008 DEC;10(4):264-70. EPUB 2008 JAN 30 PROSPECTIVE 1-YEAR MULTICENTER CASE SERIES COLLAGEN MEMBRANE WITH A HEMINERALIZED AHEAD OF PRINT21 | PERROTTI V, NICHOLLS BM STUDY WITH HISTOLOGY XENOGRAFT: A RANDOMIZED CONTROLLEDRESORPTION PATTERN OF A PORCINE-DERIVED CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 47 | SLOTTE C, LINDFORS N, NANNMARK U CLINICAL TRIALBONE SUBSTITUTE 2010 OCT 26 EPUB SURGICAL RECONSTRUCTION OF PERI-IMPLANT INTERNATIONAL JOURNAL OF PERIODONTICS ANDJOURNAL OF OSSEOINTEGRATION, 2009 RESTORATIVE DENTISTRY, 2009 FEB; 29(1):59-67 39 | SANTAGATA M, GUARINIELLO L, TARTARO G BONE DEFECTS WITH PREHYDRATED AND22 | CALVO GUIRADO JL, GOMEZ MORENO G, BARONE A MODIFIED EDENTULOUS RIDGE EXPANSION COLLAGENATED PORCINE BONE AND COLLAGEN 31 | NANNMARK U, AZARMEHR I BARRIERS: CASE PRESENTATIONSA, (MERE) TECHNIQUE FOR IMMEDIATE PLACEMENT OF SHORT COMMUNICATION: COLLAGENATED CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH,CUTANDO A, ALCARAZ BANOS M, CHIVA F, LOPEZ MARI IMPLANTS. A CASE REPORT CORTICO-CANCELLOUS PORCINE BONE GRAFTS. A 2011 DEC 6, EPUB AHEAD OF PRINTL, GUARDIA J JOURNAL OF ORAL IMPLANTOLOGY, 2010 JUN 16 STUDY IN RABBIT MAXILLARY DEFECTSMELATONIN PLUS PORCINE BONE ON DISCRETE CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 40 | BARONE A, RICCI M, CALVO GUIRADO JL, COVANI U 48 | BARONE A, RICCI M, GRASSI RF, NANNMARK U,CALCIUM DEPOSIT IMPLANT SURFACE STIMULATES 2010 JUN 1; 12(2):161-3 BONE REMODELLING AFTER REGENERATIVE QUARANTA A, COVANI UOSTEOINTEGRATION IN DENTAL IMPLANTS PROCEDURES AROUND IMPLANTS PLACED IN FRESH A 6-MONTH HISTOLOGICAL ANALYSIS ON MAXILLARY 32 | BARONE A, RICCI M, COVANI U, NANNMARK U, SINUS AUGMENTATION WITH AND WITHOUT USEJOURNAL OF PINEAL RESEARCH, 2009, 47(2):164-72 EXTRACTION SOCKETS: AN EXPERIMENTAL STUDY AZARMEHR I, CALVO GUIRADO JL OF COLLAGEN MEMBRANES OVER THE OSTEOTOMY23 | SCARANO A, PIATTELLI M, CARINCI F, PERROTTI V IN BEAGLE DOGS MAXILLARY SINUS AUGMENTATION USING WINDOW: RANDOMIZED CLINICAL TRIALREMOVAL, AFTER 7 YEARS, OF AN IMPLANT CLINICAL ORAL IMPLANTS RESEARCH, 2010 PREHYDRATED CORTICOCANCELLOUS PORCINE CLINICAL ORAL IMPLANTS RESEARCH, 2011 DEC 12,DISPLACED INTO THE MAXILLARY SINUS. A BONE: HYSTOMORPHOMETRIC EVALUATION AFTER 41 | SCARANO A, PIATTELLI A, PERROTTI V, MANZON L,CLINICAL AND HISTOLOGIC CASE REPORT IEZZI G MAXILLARY SINUS AUGMENTATION IN EPUB AHEAD OF PRINT 6 MONTHSJOURNAL OF OSSEOINTEGRATION, 2009 CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, HUMANS USING CORTICAL PORCINE BONE: A 49| SANTAGATA M, GUARINIELLO L, RAUSO R, TARTARO G24 | COVANI U, MARCONCINI S, CRESPI R, BARONE A 2010 MAY 11 EPUB HISTOLOGICAL AND HISTOMORPHOMETRICAL IMMEDIATE LOADING OF DENTAL IMPLANT AFTERIMMEDIATE IMPLANT PLACEMENT AFTER REMOVAL EVALUATION AFTER 4 AND 6 MONTHS SINUS FLOOR ELEVATION WITH OSTEOTOME 33 | CALVO GUIRADO JL, GOMEZ MORENO G, LOPEZ TECHNIQUE: A CLINICAL REPORT AND PRELIMINARYOF A FAILED IMPLANT: A CLINICAL AND CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, MARI L, RADIOGRAPHIC RESULTSHISTOLOGICAL CASE REPORT 2011 MAR; 13(1):13-18 GUARDIA J, MARINEZ GONZALEZ JM, TRESGUERRES IF, JOURNAL OF ORAL IMPLANTOLOGY, 2010 DEC; 36(6):485-489JOURNAL OF ORAL IMPLANTOLOGY, 2009; 35(4):189-95 PAREDES SD, FUENTES BRETO L 42 | CALVO GUIRADO JL, RAMIREZ FERNANDEZ MP ,25 | CALVO GUIRADO JL, GOMEZ MORENO G, LOPEZ ACTIONS OF MELATONIN MIXED WITH NEGRI B, DELGADO RUIZ RA, MATÉ SANCHEZ DE VAL JE,MARI L, COLLAGENIZED PORCINE BONE VERSUS PORCINE GOMEZ MORENO G EXPERIMENTAL MODEL OF BONEORTIZ RUIZ AJ, GUARDIA J BONE ONLY ON OSTEOINTEGRATION OF DENTAL RESPONSE TO COLLAGENIZED XENOGRAFTS OFATRAUMATIC MAXILLARY SINUS ELEVATION USING IMPLANTS PORCINE ORIGIN (OSTEOBIOL® MP3): ATHREADED BONE DILATORS FOR IMMEDIATE JOURNAL OF PINEAL RESEARCH, 2010, 48:194–203 RADIOLOGICAL AND HISTOMORPHOMETRIC STUDYIMPLANTS. A THREE-YEAR CLINICAL STUDY CLINICAL IMPLANT DENTISTRY AND RELATED RESEARCH, 34 | SCARANO A, PIATTELLI A, ASSENZA B, QUARANTA A, Source: Courtesy of Dr Ulf Nannmark, Göteborg University, SwedenMEDICINA ORAL, PATOLOGIA ORAL Y CIRUGIA BUCAL, 2011 MAR 31, EPUB AHEAD OF PRINT PERROTTI V, PIATTELLI M, IEZZI G2010 MAR 1; 15(2):E366-70 PORCINE BONE USED IN SINUS AUGMENTATION 43 | RAMIREZ FERNANDEZ MP CALVO GUIRADO JL, ,26 | FIGUEIREDO M, HENRIQUES J, MARTINS G, GUERRA PROCEDURES: A 5-YEAR RETROSPECTIVE CLINICAL DELGADO RUIZ RA, MATÉ SANCHEZ DE VAL JE, VICENTEF, JUDAS F, FIGUEIREDO H EVALUATION ORTEGA V, MESEGUER OLMOS L BONE RESPONSE TOPHYSICOCHEMICAL CHARACTERIZATION OF JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2010 HYDROXYAPATITES WITH OPEN POROSITY OF AUG; 68(8):1869-73 ANIMAL ORIGIN (PORCINE OSTEOBIOL® MP3) AND Collagenic structure of OsteoBiol® Gen-OsBIOMATERIALS COMMONLY USED IN DENTISTRY ASBONE SUBSTITUTES - COMPARISON WITH HUMAN BOVINE (ENDOBON®): A RADIOLOGICAL AND 35 | ROSSI R, MORALES RS, FRASCARIA M, BENZI R, HISTOMORPHOMETRIC STUDYBONE SQUADRITO NJOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B: CLINICAL ORAL IMPLANTS RESEARCH, 2011 JUL; PLANNING IMPLANTS IN THE ESTHETIC ZONE 22(7):767-73APPLIED BIOMATERIALS, 2010FEB; 92(2):409-19 USING A NEW IMPLANT 3D NAVIGATION SYSTEM27 | GRENGA PL, REALE G, COFONE C, MEDURI A, THE EUROPEAN JOURNAL OF ESTHETIC DENTISTRY, 2010 44| CRESPI R, CAPPARÈ P ROMANOS GE, MARIANI E, ,CERUTI P GRENGA R , SUMMER; 5(2):172-88 BENASCIUTTI E, GHERLONE EHESS AREA RATIO AND DIPLOPIA: EVALUATION OF CORTICOCANCELLOUS PORCINE BONE IN THE 36 | BARONE A, ORLANDO B, TONELLI P COVANI U , HEALING OF HUMAN EXTRACTION SOCKETS:30 PATIENTS UNDERGOING SURGICAL REPAIR FOR SURVIVAL RATE FOR IMPLANTS PLACED IN THEORBITAL BLOW-OUT FRACTURE COMBINING HISTOMORPHOMETRY WITH POSTERIOR MAXILLA WITH AND WITHOUT SINUS OSTEOBLAST GENE EXPRESSION PROFILES IN VIVOOPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, AUGMENTATION: A COMPARATIVE COHORT STUDY2009; 25(2) INTERNATIONAL JOURNAL OF ORAL AND JOURNAL OF PERIODONTOLOGY, 2011 FEB; MAXILLOFACIAL IMPLANTS, 2011 JUL-AUG; 26(4):866-72 109
  • 54. A revolutionary web site for revolutionary productswww.osteobiol.com SEARCH BY PRODUCTS SEARCH BY CLINICAL INDICATIONS WORLDWIDE EVENTS You can browse our website “by products” You can browse our website “by clinical Be always up to date with all worldwideOur new website will and compare our products characteristics indications” and let us guide you to the best OsteoBiol® eventsallow you to discover the and clinical indications solution for your clinical needsfull potential of ourbiomaterials family.On the site you will findfull products descriptionsas well as clinicalindications, cases andvideos.Enjoy osteobiol.com! BROWSE BY CLINICAL CASE REPORT BROWSE BY CLINICAL VIDEO REPORT INFORMATION FOR PATIENTS Take your time to enjoy our extensive case Take your time to enjoy our video library A powerful tool to educate your patients to a reports selection successful regenerationSource: Tecnoss Dental Media Library Source: www.osteobiol.com 110
  • 55. OsteoBiol® product codes 2012P RODUCT P ACK AG ING T YP E S IZE P ORCINE CODE E QUINE CODE BOV INE CODEBONE SU BSTITU TESGen-Os 1 Vial DRIED GRANULES 0.25g M1052FS M1052FEGen-Os 1 Vial DRIED GRANULES 0.5g M1005FS M1005FEGen-Os 1 Vial DRIED GRANULES 1.0g M1010FS M1010FEGen-Os 1 Vial DRIED GRANULES 2.0g M1020FS M1020FEmp3 1 Syringe BONE MIX 1.0cc A3005FS A3005FEmp3 3 Syringes BONE MIX 3x 0.5cc (1.5cc) A3015FS A3015FEmp3 3 Syringes BONE MIX 3x 1.0cc (3.0cc) A3030FS A3030FEPutty 1 Syringe BONE PASTE 0.5cc (1.0g) HPT09S HPT09EPutty 1 Syringe BONE PASTE 1.0cc (2.0g) HPT61S HPT61EPutty 3 Syringes BONE PASTE 3x 0.5cc (3.0g) HPT35S HPT35EPutty 3 Syringes BONE PASTE 3x 0.25cc (1.5g) HPT32S HPT32EGel 40 1 Syringe BONE GEL 0.5cc 05GEL40S 05GEL40EGel 40 3 Syringes BONE GEL 3x 0.5cc 15GEL40S 15GEL40EMEMBR ANES AND BAR R IER SEvolution 1 Blister DRIED / STANDARD 20x20x(0.5-0.7)mm EV02HHEEvolution 1 Blister DRIED / STANDARD 30x30x(0.5-0.7)mm EV03HHEEvolution 1 Blister DRIED / STANDARD Oval 25x35x(0.5-0.7)mm EVOHHEEvolution 1 Blister DRIED / FINE 20x20x(0.3-0.5)mm EV02LLEEvolution 1 Blister DRIED / FINE 30x30x(0.3-0.5)mm EV03LLEEvolution 1 Blister DRIED / FINE Oval 25x35x(0.3-0.5)mm EVOLLESoft Cortical Lamina 1 Blister DRIED / FINE 25x25x(0.4-0.6)mm LS25FS LS25FESoft Cortical Lamina 1 Blister DRIED / FINE Oval 25x35x(0.4-0.6)mm LS23FS LS23FESoft Cortical Lamina 1 Blister DRIED / FINE 20x40x(0.4-0.6)mm LS24FS LS24FESoft Cortical Lamina 1 Blister DRIED / STANDARD 30x30x(2.0-4.0)mm LS03SS LS03SECurved Lamina 1 Blister DRIED / MEDIUM 35x35x(0.8-1.0)mm LS10HS LS10HESPECIFIC PR ODU CTSApatos Mix 1 Vial DRIED GRANULES 0.5g A1005FS A1005FEApatos Mix 1 Vial DRIED GRANULES 1.0g A1010FS A1010FEApatos Mix 1 Vial DRIED GRANULES 2.0g A1020FS A1020FEApatos Cortical 1 Vial DRIED GRANULES 0.5g AC1005FSApatos Cortical 1 Vial DRIED GRANULES 1.0g AC1010FSSp-Block 1Blister DRIED BLOCK / NORM 10x10x10mm BN0ESp-Block 1Blister DRIED BLOCK / NORM 10x10x20mm BN1ESp-Block 1Blister DRIED BLOCK / NORM 10x20x20mm BN2ESp-Block 1Blister NORM 35x10x5mm BN8EDual-Block CURVED 1 Blister SOFT 20x15x5mm STS7SDual-Block 1 Blister NORM 20x15x5mm STN4BDual-Block CURVED 1 Blister NORM 20x10x5mm STN5BDual-Block CURVED 1 Blister NORM 20x20x5mm STN6BTablet 6 Blister FRIABLE DRIED BLOCK 10x10x10mm BLE10S BLE10ESpecial 1 Blister DRIED / X-FINE 20x20x(0.2)mm EM02LS EM02LESpecial 1 Blister DRIED / X-FINE 30x30x(0.2)mm EM03LS EM03LEDuo-Teck 1 Blister DRIED 20x20x(1.0)mm DT020Derma 1 Blister DRIED / STANDARD 30x30x(2.0)mm ED03SSDerma 1 Blister DRIED / FINE 25x25x(0.8-1.0)mm ED25FS 111
  • 56. OsteoBiol ® Tecnoss s.r.l. is an innovative, globally active company that develops, produces and documents premium-quality xenogenic biomaterials by the brands Tecnoss® and OsteoBiol®. Its 15 years of research led to its patent-protected production process that ensures neutralization of antigenic components in order to achieve biocompatibility. While at the same time the Tecnoss® process preserves the natural collagen matrix inside the biomaterial. Tecnoss® products comply with highest quality standards such as ISO 10993, ISO 13485 (notified body TÜV Rheinland), 93/42/EEC and 03/32/EEC (notified body CE 0373). DISTRIBUTED BYTecnoss® s.r.l. Tecnoss® Dental s.r.l.Piazza Papa Giovanni XXIII, 2 Via Torino, 2310094 Giaveno (TO), Italy 10044 Pianezza (TO), ItalyTel. +39 011 937 7347 Tel. +39 011 968 2823 MKT-CAT0112ENFax. +39 011 936 3262 Fax. +39 011 978 7577info@tecnoss.com info@tecnoss-dental.comwww.tecnoss.com www.tecnoss-dental.comBIOMATERIALS ENGINEERING INTERNATIONAL SALES & MARKETING

×